<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article
  article-type="review-article"
  dtd-version="1.3"
  xml:lang="en"
  xmlns:mml="http://www.w3.org/1998/Math/MathML"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <processing-meta
    tagset-family="jats"
    base-tagset="publishing"
    mathml-version="2.0"
    table-model="xhtml"/>
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">obm-genet</journal-id>
      <journal-title-group>
        <journal-title>OBM Genetics</journal-title>
        <abbrev-journal-title>OBM Genet</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2577-5790</issn>
      <issn-l>2577-5790</issn-l>
      <publisher>
        <publisher-name>LIDSEN Publishing Inc.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">genetics-10-04-364</article-id>
      <article-id pub-id-type="doi">10.21926/obm.genet.2604364</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Immunomodulatory Role of Stem Cells in Cancer: A Landscape of Tumor-Promoting and Tumor-Inhibitory Effects</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kanaan</surname>
            <given-names>Manal Hadi Ghaffoori</given-names>
          </name>
          <xref ref-type="aff" rid="aff-01">1</xref>
          <xref ref-type="corresp" rid="cor-01"><sup>&#x002A;</sup></xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Beom-Jin</given-names>
          </name>
          <xref ref-type="aff" rid="aff-02">2</xref>
          <xref ref-type="aff" rid="aff-03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abdullah</surname>
            <given-names>Sura Saad</given-names>
          </name>
          <xref ref-type="aff" rid="aff-02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Chulhun</given-names>
          </name>
          <xref ref-type="aff" rid="aff-04">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ghasemian</surname>
            <given-names>Abdolmajid</given-names>
          </name>
          <xref ref-type="aff" rid="aff-05">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marianne</surname>
            <given-names>Marianne</given-names>
          </name>
          <xref ref-type="aff" rid="aff-06">6</xref>
        </contrib>
        <aff id="aff-01"><label>1</label>Department of Food Industries/Technical Institute of Suwaria, Middle Technical University, Baghdad, Iraq; E-Mail: <email>dr.manalhadi@mtu.edu.iq</email></aff>
        <aff id="aff-02"><label>2</label>College of Pharmacy, Ajou University, Suwon 16499, Republic of Korea; E-Mails: <email>bjl@ajou.ac.kr</email>; <email>surasaad@ajou.ac.kr</email></aff>
        <aff id="aff-03"><label>3</label>Research Institute of Pharmaceutical Sciences and Technology, Ajou University, Suwon 16499, Republic of Korea</aff>
        <aff id="aff-04"><label>4</label>College of Pharmacy and Jeju Research Institute of Pharmaceutical Sciences, Jeju National University, Jeju 63243, Republic of Korea; E-Mail: <email>chpark@jejunu.ac.kr</email></aff>
        <aff id="aff-05"><label>5</label>Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran; E-Mail: <email>majidghasemian86@gmail.com</email></aff>
        <aff id="aff-06"><label>6</label>Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia; E-Mail: <email>marianne80@usu.ac.id</email></aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Bennett</surname>
            <given-names>Lunawati L</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="cor-01"><label>&#x002A;</label>Correspondence: Manal Hadi Ghaffoori Kanaan; E-Mail: <email>dr.manalhadi@mtu.edu.iq</email></corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic" iso-8601-date="2026-10-30">
        <day>30</day>
        <month>10</month>
        <year>2026</year>
      </pub-date>
      <volume>10</volume>
      <issue>4</issue>
      <elocation-id>364</elocation-id>
      <history>
        <date date-type="received" iso-8601-date="2026-07-17">
          <day>17</day>
          <month>07</month>
          <year>2026</year>
        </date>
        <date date-type="accepted" iso-8601-date="2026-10-25">
          <day>25</day>
          <month>10</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#x00A9; 2026 by the authors.</copyright-statement>
        <copyright-year>2026</copyright-year>
        <license license-type="open-access">
          <license-p>This is an open access article distributed under the conditions of the <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/2.0/">Creative Commons by Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Stem cell therapy has emerged as a transformative frontier in cancer treatment, harnessing the unique immunomodulatory capabilities of stem cells to reshape anti-tumor immune responses. Mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), and cancer stem cells (CSCs) dynamically interact with innate and adaptive immune systems within the tumor microenvironment (TME). MSCs secrete cytokines such as IL-6, TGF-&#x03B2;, and VEGF, which exhibit context-dependent effects on cytotoxic T lymphocytes (CTLs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs). These effects vary according to factors such as MSC tissue origin, tumor type, inflammatory status, and the cytokine milieu. MSCs can also modulate tumor-associated macrophage (TAM) polarization, but the direction of polarization toward pro-tumor M2-like or anti-tumor M1-like phenotypes is highly dependent on the surrounding TME. Conversely, CSCs drive immune evasion by expressing checkpoint molecules (e.g., PD-L1) and recruiting immunosuppressive cells, illustrating stem cells&#x2019; paradoxical roles in cancer progression. Despite their promise, challenges persist: the TME&#x2019;s complexity, safety concerns (tumorigenicity, immune rejection), and a lack of standardized protocols impede clinical translation. Innovations such as genetically engineered stem cells for targeted drug delivery, their potential combination with immunotherapies such as CAR-T cells and checkpoint inhibitors, and personalized approaches tailored to tumor-specific profiles offer promising experimental strategies to enhance efficacy. This review underscores stem cells&#x2019; potential role in rebalancing immune responses while emphasizing the need for further research to refine their therapeutic application. Although hematopoietic stem cell transplantation is clinically established for selected hematological malignancies, most other stem-cell-based immunomodulatory approaches remain preclinical or are under early clinical investigation.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Stem cells</kwd>
        <kwd>cancer</kwd>
        <kwd>immunotherapy</kwd>
        <kwd>immunomodulation</kwd>
        <kwd>mesenchymal stem cells</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
      <sec id="sec-01">
        <label>1.</label>
        <title>Introduction</title>
        <p>Stem cell therapy represents a frontier in regenerative medicine and cancer treatment, offering novel strategies to address the limitations of conventional therapeutic approaches [<xref ref-type="bibr" rid="B-001">1</xref>]. Stem cells can self-renew and differentiate into diverse cell types, making them valuable for tissue repair, regenerative medicine, and targeted drug delivery [<xref ref-type="bibr" rid="B-002">2</xref>]. Their ability to modulate the immune system has garnered considerable attention, particularly in cancer therapy [<xref ref-type="bibr" rid="B-003">3</xref>].</p>
        <p>Stem cells are undifferentiated cells characterized by self-renewal, enabling them to replicate and maintain a pool of undifferentiated cells, and differentiation, allowing them to mature into specialized cell types with specific functions. This dual capacity is fundamental to their role in tissue homeostasis, repair, and regeneration. Several types of stem cells with unique characteristics have therapeutic applications [<xref ref-type="bibr" rid="B-004">4</xref>]. Importantly, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), and cancer stem cells (CSCs) have fundamentally different roles in cancer immunity: MSCs mainly exert paracrine immunomodulatory effects, HSCs generate hematopoietic and immune-cell lineages, iPSCs provide a renewable source for generating specialized immune cells, whereas CSCs are malignant stem-like cells involved in immune evasion and therapeutic resistance [<xref ref-type="bibr" rid="B-004">4</xref>].</p>
        <p>Stem cell therapy has broad applications, including regenerative medicine, where stem cells are employed to repair or replace damaged tissues and organs, offering hope for treating conditions such as heart disease, neurodegenerative disorders, and spinal cord injuries [<xref ref-type="bibr" rid="B-005">5</xref>]. In cancer therapy, stem cells can serve as therapeutic carriers for targeted drug delivery to tumor sites, selectively target CSCs to eradicate the root of the tumor, and modulate the immune system to enhance anti-tumor immune responses [<xref ref-type="bibr" rid="B-002">2</xref>,<xref ref-type="bibr" rid="B-006">6</xref>]. Immunomodulation in cancer therapy involves modulating the immune system to better recognize and eliminate cancer cells, shifting the balance from tumor-promoting inflammation to anti-tumor immunity [<xref ref-type="bibr" rid="B-007">7</xref>,<xref ref-type="bibr" rid="B-008">8</xref>]. This can be achieved by stimulating anti-tumor immune responses, suppressing immunosuppressive mechanisms that protect cancer cells from immune attack, and restoring immune homeostasis to create an environment less conducive to tumor growth [<xref ref-type="bibr" rid="B-009">9</xref>]. Stem cells, particularly MSCs, play a pivotal role in immunomodulation by interacting with various immune cells, secreting cytokines and growth factors that influence immune cell behavior, and influencing immune cell differentiation and function, shaping the immune landscape within the tumor microenvironment (TME) [<xref ref-type="bibr" rid="B-006">6</xref>,<xref ref-type="bibr" rid="B-010">10</xref>]. By modulating the immune system, stem cells can improve cancer therapy efficacy, overcome therapeutic resistance mechanisms used by cancer cells, and improve patient outcomes, offering a more personalized, targeted approach to cancer treatment [<xref ref-type="bibr" rid="B-008">8</xref>].</p>
        <sec id="sec-01-01">
          <label>1.1</label>
          <title>Literature Search Strategy</title>
          <p>This narrative review was based on literature searches conducted in PubMed, Scopus, and Google Scholar using combinations of the terms &#x201C;stem cells,&#x201D; &#x201C;mesenchymal stem cells,&#x201D; &#x201C;hematopoietic stem cells,&#x201D; &#x201C;induced pluripotent stem cells,&#x201D; &#x201C;cancer stem cells,&#x201D; &#x201C;cancer,&#x201D; &#x201C;immunomodulation,&#x201D; &#x201C;tumor microenvironment,&#x201D; &#x201C;T cells,&#x201D; &#x201C;NK cells,&#x201D; &#x201C;macrophages,&#x201D; &#x201C;regulatory T cells,&#x201D; &#x201C;myeloid-derived suppressor cells,&#x201D; and &#x201C;immune evasion.&#x201D; We considered studies published primarily between 2009 and 2026, and included relevant earlier studies when necessary. We included original studies, clinical studies, and relevant reviews on stem-cell-mediated cancer immunomodulation, and excluded studies without a clear link to cancer immunity or outside the scope of this review.</p>
        </sec>
      </sec>
      <sec id="sec-02">
        <label>2.</label>
        <title>Cross-Talk of Stem Cells and the Immune System in Cancer</title>
        <sec id="sec-02-01">
          <label>2.1</label>
          <title>Overview of Immune Responses in Cancer</title>
          <p>The immune system plays a complex and multifaceted role in cancer, characterized by both protective and promoting effects that significantly influence tumor development and progression [<xref ref-type="bibr" rid="B-011">11</xref>]. Understanding the intricate interplay between innate and adaptive immunity is paramount for devising effective immunotherapeutic strategies that harness the immune system&#x2019;s anti-tumor potential.</p>
          <p>Innate immunity constitutes the body&#x2019;s initial line of defense against pathogens and aberrant cells, including cancer cells, and involves a diverse array of cells such as macrophages, natural killer (NK) cells, and dendritic cells (DCs) [<xref ref-type="bibr" rid="B-012">12</xref>]. Macrophages, versatile phagocytes, can engulf and digest cancer cells, while also presenting tumor-associated antigens to adaptive immune cells, thereby initiating a targeted anti-tumor response. NK cells, specialized cytotoxic lymphocytes, can directly recognize and kill cancer cells without prior sensitization, providing rapid and broad-spectrum anti-tumor activity [<xref ref-type="bibr" rid="B-013">13</xref>]. DCs function as professional antigen-presenting cells (APCs), capturing, processing, and presenting tumor-associated antigens to T cells, thereby bridging the innate and adaptive immune responses and initiating a targeted anti-tumor response [<xref ref-type="bibr" rid="B-014">14</xref>]. Myeloid-derived suppressor cells (MDSCs), a heterogeneous population of immature myeloid cells, represent another component of the innate immune system, but they typically exert immunosuppressive effects within the TME, suppressing anti-tumor immune responses and promoting tumor growth and metastasis [<xref ref-type="bibr" rid="B-015">15</xref>].</p>
          <p>Adaptive immunity, a more refined and targeted defense mechanism, involves T and B lymphocytes, which recognize specific tumor-associated antigens and mount tailored immune responses to eradicate cancer cells [<xref ref-type="bibr" rid="B-016">16</xref>]. T cells, including cytotoxic T lymphocytes (CTLs) and helper T cells, directly kill cancer cells and coordinate immune responses by secreting cytokines that modulate other immune cells [<xref ref-type="bibr" rid="B-006">6</xref>]. B cells, responsible for humoral immunity, produce antibodies that can neutralize tumor antigens, activate the complement system to destroy cancer cells, and mediate antibody-dependent cell-mediated cytotoxicity (ADCC), recruiting immune cells to eliminate antibody-coated cancer cells. Regulatory T cells (Tregs), a subset of T cells, suppress immune responses to maintain immune homeostasis and prevent autoimmunity, but in cancer, they can also inhibit anti-tumor immunity within the TME, protecting cancer cells from immune attack [<xref ref-type="bibr" rid="B-017">17</xref>].</p>
        </sec>
        <sec id="sec-02-02">
          <label>2.2</label>
          <title>Interaction Between Stem Cells and Immune Cells</title>
          <p>Different stem cell populations interact with immune cells, influencing the balance between anti-tumor immunity and immune suppression and thereby affecting tumor growth and progression [<xref ref-type="bibr" rid="B-018">18</xref>,<xref ref-type="bibr" rid="B-019">19</xref>]. For MSCs, these interactions are mainly mediated by cell-cell contact, cytokine secretion, and other signaling mechanisms and can either stimulate or suppress immune-cell activity depending on the surrounding microenvironment [<xref ref-type="bibr" rid="B-020">20</xref>]. HSCs primarily contribute through hematopoietic and immune-cell generation, whereas iPSCs can serve as a source of differentiated immune effector cells. CSCs, in contrast, predominantly interact with immune cells to facilitate immune evasion. For example, mesenchymal stem cells (MSCs), known for their immunomodulatory properties, can interact with NK cells, suppressing their proliferation, cytokine secretion, and cytotoxicity, thereby potentially dampening the innate immune response against cancer [<xref ref-type="bibr" rid="B-021">21</xref>]. However, activated NK cells can also lyse MSCs, highlighting a complex bidirectional interaction in which NK cells can eliminate MSCs that may pose a threat. MSCs can modulate DC differentiation, maturation, and function, influencing their ability to present tumor-associated antigens to T cells and initiate a targeted adaptive immune response [<xref ref-type="bibr" rid="B-020">20</xref>,<xref ref-type="bibr" rid="B-022">22</xref>].</p>
          <p>Tumor-associated macrophages (TAMs), a prominent component of the TME, interact extensively with CSCs to promote tumor progression, maintain CSC stemness, and enhance their resistance to therapy [<xref ref-type="bibr" rid="B-023">23</xref>]. TAMs can secrete growth factors, cytokines, and other factors that enhance CSC self-renewal, proliferation, and drug resistance, while CSCs recruit macrophages into the TME, creating a self-reinforcing loop that promotes tumor growth and immune evasion. The interactions between TAMs and CSCs exemplify the complex interplay between stem cells and immune cells within the TME, highlighting the challenges in developing effective cancer immunotherapies [<xref ref-type="bibr" rid="B-024">24</xref>].</p>
        </sec>
      </sec>
      <sec id="sec-03">
        <label>3.</label>
        <title>Mechanisms of Immunomodulation by Stem Cells in Cancer</title>
        <p>Stem cells, particularly MSCs, exert immunomodulatory effects in the TME through multifaceted mechanisms, including the secretion of cytokines (e.g., IL-6, IL-8, VEGF, TGF-&#x03B2;, IL-10) and chemokines (e.g., MCP-1, MIP-1), direct cell-cell interactions, and recruitment of immune cells such as neutrophils, macrophages, T cells, Tregs, and MDSCs [<xref ref-type="bibr" rid="B-025">25</xref>,<xref ref-type="bibr" rid="B-026">26</xref>]. These secreted factors modulate immune responses by influencing immune cell differentiation, activation, and function: pro-inflammatory cytokines can enhance anti-tumor immunity by recruiting cytotoxic T cells and NK cells, while immunosuppressive cytokines like TGF-&#x03B2; and IL-10 suppress T cell activity and promote tolerance. MSCs also alter macrophage polarization, shifting the balance between anti-tumor M1 (pro-inflammatory) and pro-tumor M2 (anti-inflammatory) phenotypes, and regulate T cell function [<xref ref-type="bibr" rid="B-025">25</xref>,<xref ref-type="bibr" rid="B-027">27</xref>,<xref ref-type="bibr" rid="B-028">28</xref>]. Importantly, MSC-mediated regulation of Tregs, MDSCs, macrophages, and effector lymphocytes is context-dependent and can either enhance or suppress anti-tumor immunity according to MSC origin, activation status, tumor type, and the surrounding cytokine milieu. The complexity and context-dependence of these interactions, including their impact on the inflammatory landscape and immune cell dynamics, underscore the need for further research to optimize stem cell-based therapies for enhancing anti-tumor efficacy while mitigating immune suppression in the TME [<xref ref-type="bibr" rid="B-029">29</xref>] (<xref ref-type="table" rid="T-01">Table 1</xref>).</p>
        <table-wrap id="T-01" orientation="portrait" position="anchor">
          <label>Table 1</label>
          <caption>
            <title>Studies on the immunomodulatory role of stem cells in cancer.</title>
          </caption>
          <table frame="lhs" rules="none">
            <thead>
              <tr>
                <td align="left" valign="middle">Author(s)</td>
                <td align="left" valign="middle">Stem cell type</td>
                <td align="left" valign="middle">Cancer type</td>
                <td align="left" valign="middle">Main findings</td>
                <td align="left" valign="middle">Reference</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" valign="middle">Yu et al.</td>
                <td align="left" valign="middle">
                  <p>HCT116</p>
                  <p>(colon cancer</p>
                  <p>stem cells)</p>
                </td>
                <td align="left" valign="middle">Colon Cancer</td>
                <td align="left" valign="middle">TP5 reduces stemness in HCT116 cells, enhancing the cytotoxic effect of oxaliplatin by decreasing stemness-related markers and altering Wnt/&#x03B2;-catenin signaling.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-030">30</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Casbon et al.</td>
                <td align="left" valign="middle">HSC</td>
                <td align="left" valign="middle">Breast Cancer</td>
                <td align="left" valign="middle">Tumor-derived G-CSF directs hematopoietic stem cells to produce immunosuppressive neutrophils, contributing to immune evasion.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-031">31</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Pont et al.</td>
                <td align="left" valign="middle">HSC</td>
                <td align="left" valign="middle">
                  <p>Hematological</p>
                  <p>Malignancies</p>
                </td>
                <td align="left" valign="middle">The study demonstrates the immunotherapeutic potential of donor T cells post-alloSCT and the necessity of analyzing antigen distribution to avoid adverse effects.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-032">32</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Lullo et al.</td>
                <td align="left" valign="middle">HSC</td>
                <td align="left" valign="middle">
                  <p>Multiple</p>
                  <p>Myeloma</p>
                </td>
                <td align="left" valign="middle">IMiDs reduce pro-tumor T cell subsets in MM during autologous transplantation, suggesting an anti-inflammatory role.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-033">33</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Sayed et al.</td>
                <td align="left" valign="middle">HSC</td>
                <td align="left" valign="middle">
                  <p>Various Murine</p>
                  <p>Tumors</p>
                </td>
                <td align="left" valign="middle">Activation of myelopoiesis and MDSC differentiation in tumor models lead to immunosuppression.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-034">34</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Lee et al.</td>
                <td align="left" valign="middle">HSC</td>
                <td align="left" valign="middle">Ovarian Cancer</td>
                <td align="left" valign="middle">CD8&#x03B1;+ dendritic cells from HSCs enhance antitumor immune activity against ovarian cancer.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-035">35</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Rossnagl et al.</td>
                <td align="left" valign="middle">Osteoblasts</td>
                <td align="left" valign="middle">Various cancer</td>
                <td align="left" valign="middle">EDA-FN from osteoblasts increases arginase in myeloid-derived cells, promoting cancer growth via immune modulation.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-036">36</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Witte et al.</td>
                <td align="left" valign="middle">MSC</td>
                <td align="left" valign="middle">Lung Cancer</td>
                <td align="left" valign="middle">MSCs trigger immunomodulation through phagocytosis by monocytic cells, suggesting a mechanism for their therapeutic effects despite their rapid disappearance.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-037">37</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Wellhausen et al.</td>
                <td align="left" valign="middle">HSC</td>
                <td align="left" valign="middle">Acute Myeloid Leukemia, B cell lymphoma, Acute T cell leukemia</td>
                <td align="left" valign="middle">Development of epitope edited CD45 CAR T cells enables universal therapy against blood cancers; protects HSCs from CAR T cell recognition and destruction.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-038">38</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Rueff et al.</td>
                <td align="left" valign="middle">HSC</td>
                <td align="left" valign="middle">Plasma Cell Myeloma</td>
                <td align="left" valign="middle">Rapid recovery of NK cells after autologous HSCT correlates with protection from relapse in patients.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-039">39</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Zhang et al.</td>
                <td align="left" valign="middle">MSC</td>
                <td align="left" valign="middle">Various</td>
                <td align="left" valign="middle">Tumor-conditioned MSCs display hematopoietic differentiation, with a diminished Ca<sup>2+</sup> influx facilitating the conversion to immune cells like macrophages.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-040">40</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Giles et al.</td>
                <td align="left" valign="middle">MSC</td>
                <td align="left" valign="middle">Metastatic Tumors</td>
                <td align="left" valign="middle">HSPCs contribute to immunosuppression within pre-metastatic niches, impacting tumor dissemination.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-041">41</xref>]</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Wu et al.</td>
                <td align="left" valign="middle">Hematopoietic Stem and Progenitor Cells</td>
                <td align="left" valign="middle">Various cancers</td>
                <td align="left" valign="middle">The study reveals that HSPCs in cancer patients are myeloid-biased, contributing to the accumulation of MDSCs and disease progression.</td>
                <td align="left" valign="middle">[<xref ref-type="bibr" rid="B-042">42</xref>]</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <sec id="sec-03-01">
          <label>3.1</label>
          <title>Cytokine and Growth Factor Secretion</title>
          <p>Stem cells exert significant immunomodulatory effects in cancer by secreting cytokines and growth factors, soluble mediators that influence immune cells, tumor cells, and other TME components, ultimately affecting tumor growth and the overall immune response [<xref ref-type="bibr" rid="B-043">43</xref>]. These secreted factors can act locally within the TME or systemically, influencing immune cell trafficking, differentiation, and function.</p>
          <p>Cytokines are signaling molecules that mediate communication between cells and play a crucial role in regulating immune responses, orchestrating the complex interactions among immune cell types and influencing the balance between pro-inflammatory and anti-inflammatory responses [<xref ref-type="bibr" rid="B-044">44</xref>]. Stem cells, particularly MSCs, secrete a wide array of cytokines that can either promote or suppress immune responses, depending on the specific context and the target cells involved. For instance, MSCs secrete IL-6, which can have dual effects depending on the context, promoting tumor growth and angiogenesis in some cases, while contributing to inflammatory immune activation under other conditions [<xref ref-type="bibr" rid="B-045">45</xref>,<xref ref-type="bibr" rid="B-046">46</xref>]. The net effect depends on tumor type, the cellular source of IL-6, its concentration, and activation of downstream pathways such as STAT3. Similarly, IL-8 secreted by MSCs can attract neutrophils and other immune cells to the TME, modulating the inflammatory landscape and potentially influencing tumor progression [<xref ref-type="bibr" rid="B-047">47</xref>].</p>
          <p>TGF-&#x03B2; is another important cytokine secreted by MSCs, known for its immunosuppressive properties, inhibiting the activation and proliferation of T cells, promoting the differentiation of Tregs, and suppressing the activity of NK cells. These effects can contribute to immune evasion by cancer cells. However, TGF-&#x03B2; can also have anti-tumor effects by inhibiting tumor-cell proliferation and inducing apoptosis, particularly during earlier stages of tumorigenesis, highlighting the complex and context-dependent nature of cytokine signaling in cancer [<xref ref-type="bibr" rid="B-048">48</xref>].</p>
          <p>Stem cells also secrete growth factors that influence tumor growth, angiogenesis, and immune cell function, shaping the TME and influencing the course of tumor development. VEGF is a key growth factor secreted by stem cells, promoting angiogenesis and tumor vascularization, providing tumors with the nutrients and oxygen they need to grow and metastasize. By promoting angiogenesis, VEGF can enhance tumor growth and metastasis. However, VEGF can also modulate immune cell function by suppressing the maturation of DCs and inhibiting T cell responses, further contributing to immune evasion [<xref ref-type="bibr" rid="B-049">49</xref>,<xref ref-type="bibr" rid="B-050">50</xref>].</p>
          <p>The specific effects of stem cell-derived cytokines on tumor growth and immune response depend on several factors, including stem cell type, the TME, and the specific cytokines involved, making it challenging to predict the overall impact of stem cell therapy on cancer progression [<xref ref-type="bibr" rid="B-051">51</xref>]. Understanding these complex interactions is crucial for developing effective stem cell-based immunotherapies that can harness the beneficial effects of cytokines while minimizing their potential to promote tumor growth. For example, human Wharton&#x2019;s jelly stem cells (hWJSCs) secrete cytokines that inhibit the proliferation of ovarian cancer cells in vitro, suggesting their potential as a therapeutic agent. These hWJSC extracts decreased the expression of oncogenic cytokines, chemokines, and growth factors, thereby inhibiting OVCAR3 cells, demonstrating their ability to modulate the cytokine milieu within the TME [<xref ref-type="bibr" rid="B-052">52</xref>].</p>
        </sec>
        <sec id="sec-03-02">
          <label>3.2</label>
          <title>Regulation of Tumor-Associated Macrophages</title>
          <p>TAMs are a key component of the TME and play a critical role in tumor progression and immune evasion, influencing angiogenesis, metastasis, and therapeutic resistance [<xref ref-type="bibr" rid="B-053">53</xref>]. Stem cells can influence macrophage polarization, affecting the balance between M1 and M2 macrophages, which have opposing roles in tumor immunity, with M1 macrophages generally exhibiting anti-tumor activity and M2 macrophages promoting tumor growth [<xref ref-type="bibr" rid="B-054">54</xref>].</p>
          <p>Macrophages exhibit remarkable plasticity, adapting their phenotype and function in response to environmental signals, and can differentiate into functionally distinct phenotypes, primarily classified as M1 and M2 macrophages [<xref ref-type="bibr" rid="B-055">55</xref>]. M1 macrophages are classically activated by stimuli such as IFN-&#x03B3; and lipopolysaccharide (LPS) and exert anti-tumor functions, producing pro-inflammatory cytokines such as IL-12 and TNF-&#x03B1;, mediating cytotoxicity, and promoting T cell responses. In contrast, M2 macrophages are alternatively activated by stimuli such as IL-4 and IL-10 and promote tumor progression, secreting anti-inflammatory cytokines such as IL-10 and TGF-&#x03B2;, promoting angiogenesis, and suppressing T cell responses [<xref ref-type="bibr" rid="B-056">56</xref>].</p>
          <p>MSCs can influence macrophage polarization in a context-dependent manner, potentially shifting macrophages toward either M1-like or M2-like phenotypes. For example, MSCs can secrete factors (e.g., TNF-&#x03B1;, IL-1&#x03B2;, IL-6, IL-12, IL-23, and CXCL10) that promote M1 polarization, enhancing anti-tumor immunity and increasing pro-inflammatory cytokine production [<xref ref-type="bibr" rid="B-057">57</xref>]. Conversely, stem cells can also promote M2 polarization, contributing to immune suppression and tumor progression by secreting factors that suppress T cell activity and promote angiogenesis [<xref ref-type="bibr" rid="B-058">58</xref>]. Thus, the inflammatory environment, tumor-derived signals, and the functional state of MSCs determine MSC-mediated macrophage polarization.</p>
          <p>TAMs play a critical role in tumor progression and immune evasion, influencing various aspects of tumor biology. M2 macrophages promote tumor growth by secreting growth factors and cytokines that stimulate tumor cell proliferation and angiogenesis, providing tumors with the resources they need to grow and metastasize [<xref ref-type="bibr" rid="B-059">59</xref>]. They also suppress anti-tumor immune responses by inhibiting T cell activation and promoting the differentiation of Tregs, creating an immunosuppressive environment that protects cancer cells from immune attack. TAMs can also contribute to CSC maintenance and drug resistance, promoting tumor recurrence and therapeutic failure [<xref ref-type="bibr" rid="B-060">60</xref>].</p>
          <p>Targeting TAMs has emerged as a promising strategy for cancer immunotherapy, aiming to reprogram their function and enhance anti-tumor immunity. Strategies include depleting TAMs, inhibiting their recruitment to the TME, and reprogramming M2 macrophages to M1 macrophages, shifting the balance from tumor-promoting inflammation to anti-tumor immunity [<xref ref-type="bibr" rid="B-061">61</xref>]. Preclinical approaches targeting innate immune signaling pathways, including STING activation, can also alter TAM function [<xref ref-type="bibr" rid="B-024">24</xref>]. Stem cells can deliver therapeutic agents directly to TAMs, modulating their function and promoting anti-tumor immunity, offering a targeted approach to reprogram the TME. For instance, MSCs can deliver oncolytic Newcastle disease virus (NDV) to enhance therapeutic effects by altering the TME and promoting apoptosis, demonstrating stem cells' potential to modulate TAM function [<xref ref-type="bibr" rid="B-062">62</xref>]. However, clinicians have not yet established durable MSC-mediated TAM reprogramming.</p>
        </sec>
        <sec id="sec-03-03">
          <label>3.3</label>
          <title>Modulation of T-Cell Responses</title>
          <p>T cells are critical components of the adaptive immune system, recognizing and eliminating cancer cells through direct cytotoxicity and the secretion of cytokines that coordinate immune responses. Stem cells can influence T-cell activation, differentiation, and function, affecting their ability to mount effective anti-tumor responses and impacting the course of cancer progression [<xref ref-type="bibr" rid="B-063">63</xref>].</p>
          <p>T-cell activation is a complex process that requires multiple signals, including antigen presentation by APCs and co-stimulatory signals that provide the necessary cues for T-cell proliferation and effector function [<xref ref-type="bibr" rid="B-064">64</xref>]. Stem cells can modulate T-cell activation by influencing APC function, altering the expression of co-stimulatory molecules (i.e., CD80/CD86, CD40, PD-L1, ICOS-L, and CTLA-4), and secreting cytokines that affect T-cell signaling pathways [<xref ref-type="bibr" rid="B-065">65</xref>]. For example, MSCs can suppress T-cell proliferation and activation by secreting TGF-&#x03B2; and IL-10, inhibiting pro-inflammatory cytokine production and dampening the overall immune response [<xref ref-type="bibr" rid="B-066">66</xref>].</p>
          <p>Stem cells also influence T-cell differentiation, the process by which T cells acquire specialized functions, affecting the balance among T-cell subsets such as CTLs, helper T cells, and Tregs [<xref ref-type="bibr" rid="B-067">67</xref>]. CTLs are critical for directly killing cancer cells, while helper T cells coordinate immune responses through cytokine secretion, activating other immune cells and enhancing anti-tumor immunity. Tregs, on the other hand, suppress immune responses to prevent autoimmunity but can also inhibit anti-tumor immunity in the TME, protecting cancer cells from immune attack [<xref ref-type="bibr" rid="B-068">68</xref>].</p>
          <p>Stem-cell-based approaches can modulate T-cell-mediated anti-tumor immunity, although the direction of this effect depends strongly on the stem cell type and experimental context. Engineered MSC-based strategies may promote CTL responses, whereas unmodified MSCs frequently suppress T-cell activation through immunoregulatory mediators. Similarly, their effects on Tregs may vary according to the cytokine environment and MSC activation state [<xref ref-type="bibr" rid="B-069">69</xref>]. By modulating T-cell responses, stem-cell-based approaches may influence the efficacy of cancer therapies [<xref ref-type="bibr" rid="B-070">70</xref>].</p>
          <p>The potential therapeutic effects of stem cells on T-cell-mediated anti-tumor immunity have been demonstrated, providing evidence that they can enhance T-cell activity and promote tumor regression. For instance, MSCs loaded with oncolytic NDV can enhance E7-specific lymphocyte proliferation and CD8+ cytolysis, increasing the number of T cells targeting tumor-associated antigens and enhancing their cytotoxic activity [<xref ref-type="bibr" rid="B-071">71</xref>]. Additionally, a strategy combining 4-methylumbelliferone (4Mu) with an adenovirus encoding interleukin-12 (AdIL-12) elicited a potent anti-tumor effect and prolonged animal survival by promoting cytotoxic-specific T cell responses, demonstrating the ability of stem cells to enhance T cell-mediated immunity [<xref ref-type="bibr" rid="B-072">72</xref>].</p>
        </sec>
        <sec id="sec-03-04">
          <label>3.4</label>
          <title>Regulation of Regulatory T-Cells and Myeloid-Derived Suppressor Cells</title>
          <p>As mentioned, Tregs and MDSCs are major players in immune suppression in the TME, inhibiting anti-tumor immune responses and promoting tumor growth and metastasis. These cells use various mechanisms to suppress immune cell activity, creating a protective shield around cancer cells and hindering immune elimination. Stem cells, particularly MSCs, can modulate the function of Tregs and MDSCs; however, these effects may be either suppressive or supportive depending on the surrounding inflammatory and tumor context [<xref ref-type="bibr" rid="B-073">73</xref>]. Tregs can inhibit anti-tumor immunity, promoting tumor growth and immune evasion by suppressing the activity of effector T cells and other immune cells that would otherwise target and kill cancer cells [<xref ref-type="bibr" rid="B-074">74</xref>]. Tregs suppress T-cell activation and proliferation via inhibitory cytokines (TGF-&#x03B2;, IL-10), metabolic disruption (adenosine/CD39-CD73), and CTLA-4-mediated competition for co-stimulatory signals (CD80/CD86); inhibit NK cell activity by downregulating activating receptors (e.g., NKG2D) through TGF-&#x03B2;/IL-10 and inducing exhaustion via PD-1/PD-L1 or granzyme B; and promote MDSC differentiation through GM-CSF, CD40-CD40L interactions, and miRNA transfer, amplifying their arginase-1/iNOS-dependent immunosuppression. This establishes a self-reinforcing network within the TME, bolstered by crosstalk with M2-like macrophages, CAFs, and chemokine-driven recruitment of suppressive cells [<xref ref-type="bibr" rid="B-075">75</xref>].</p>
          <p>Also, MDSCs inhibit T cell activation and proliferation, promote Treg differentiation, and suppress NK cell activity, contributing to generalized immune suppression within the TME [<xref ref-type="bibr" rid="B-076">76</xref>]. MDSCs also promote angiogenesis, tumor cell proliferation, and metastasis, facilitating tumor progression and dissemination to distant sites [<xref ref-type="bibr" rid="B-077">77</xref>]. MSCs can regulate Tregs and MDSCs through several context-dependent mechanisms [<xref ref-type="bibr" rid="B-078">78</xref>,<xref ref-type="bibr" rid="B-079">79</xref>]. Although some experimental conditions have been associated with reduced suppressive activity, MSC-derived factors such as TGF-&#x03B2; and IL-10 can also support Treg-mediated immunosuppression. Similarly, MSC effects on MDSCs vary according to tumor-derived signals and the inflammatory environment. Therefore, MSC-mediated regulation of Tregs and MDSCs should not be considered uniformly anti-tumor [<xref ref-type="bibr" rid="B-079">79</xref>].</p>
          <p>The mechanisms by which stem cells inhibit immune suppression in cancer are complex and context-dependent, requiring further investigation to fully elucidate their intricacies and optimize their therapeutic potential [<xref ref-type="bibr" rid="B-080">80</xref>]. Understanding these mechanisms is crucial for designing effective stem cell-based immunotherapies that can selectively target Tregs and MDSCs while sparing other immune cells, maximizing anti-tumor immunity and minimizing off-target effects. For instance, oncolytic NDV delivered by MSCs can increase infiltration of CD11b<sup>+</sup>Gr1<sup>+</sup> MDSCs, suggesting a modulation of the TME and a potential shift in MDSC function [<xref ref-type="bibr" rid="B-081">81</xref>]. Additionally, SF2523, a dual PI3K/BRD4 inhibitor, blocks tumor immunosuppression and promotes adaptive immune responses by reducing the infiltration of MDSCs and the polarization of immunosuppressive macrophages, highlighting the potential of targeted therapies to modulate immune cell activity [<xref ref-type="bibr" rid="B-082">82</xref>] (<xref ref-type="fig" rid="F-01">Figure 1</xref>).</p>
          <fig id="F-01" orientation="portrait" position="float">
            <label>Figure 1</label>
            <caption>
              <p>Mechanisms of MSC-mediated immunomodulation in cancer. This schematic illustrates the context-dependent effects of mesenchymal stem cells (MSCs) on immune responses within the tumor microenvironment (TME). (a) Cytokine release: MSCs release interleukin-6 (IL-6), transforming growth factor-beta (TGF-&#x03B2;), vascular endothelial growth factor (VEGF), and interleukin-10 (IL-10). The predominant immunoregulatory effects of MSC-derived TGF-&#x03B2; include regulatory T-cell (Treg) differentiation and suppression of effector T-cell activity. IL-6 has context-dependent effects, whereas VEGF promotes angiogenesis and IL-10 contributes to immunosuppression. (b) Macrophage polarization: MSCs influence tumor-associated macrophage (TAM) polarization toward M1-associated anti-tumor activity or M2-associated angiogenesis and immunosuppression. (c) Context-dependent anti-tumor effects: Under specific conditions, MSC-mediated modulation may promote cytotoxic T-lymphocyte (CTL) activation and inhibit Treg activity; these effects are distinct from the predominant immunosuppressive effects of MSC-derived TGF-&#x03B2;. (d) Context-dependent MDSC modulation: MSCs may reduce myeloid-derived suppressor cell (MDSC)-mediated T-cell suppression under specific conditions. Solid arrows indicate activation or differentiation, inhibitory lines indicate suppression, and dashed arrows indicate indirect or context-dependent immunomodulatory effects. Context-dependent effects are additionally identified by explicit labels. Abbreviations: MSC, mesenchymal stem cell; TME, tumor microenvironment; IL, interleukin; TGF-&#x03B2;, transforming growth factor-beta; VEGF, vascular endothelial growth factor; TAM, tumor-associated macrophage; Treg, regulatory T cell; CTL, cytotoxic T lymphocyte; MDSC, myeloid-derived suppressor cell.</p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure01.jpg"/>
          </fig>
        </sec>
      </sec>
      <sec id="sec-04">
        <label>4.</label>
        <title>Types of Stem Cells Enrolled in Cancer Immunomodulation</title>
        <sec id="sec-04-01">
          <label>4.1</label>
          <title>Mesenchymal Stem Cells</title>
          <p>MSCs are multipotent stromal cells that can differentiate into various cell types, including osteocytes, chondrocytes, and adipocytes, making them valuable for regenerative medicine and tissue engineering [<xref ref-type="bibr" rid="B-083">83</xref>]. MSCs possess inherent immunomodulatory properties, making them attractive candidates for cell-based therapies in cancer, where they can modulate the immune system to enhance anti-tumor responses [<xref ref-type="bibr" rid="B-084">84</xref>]. MSCs exert their immunomodulatory effects through diverse mechanisms, including the secretion of cytokines, direct cell-cell interactions with immune cells, and the modulation of immune cell function, creating a complex interplay between MSCs and the immune system [<xref ref-type="bibr" rid="B-085">85</xref>]. MSCs can secrete immunosuppressive cytokines such as TGF-&#x03B2; and IL-10, which inhibit T cell proliferation and activation, dampening immune responses and promoting immune tolerance [<xref ref-type="bibr" rid="B-086">86</xref>]. They can also modulate immune cells such as macrophages, NK cells, and DCs, influencing their activity and shaping the immune landscape within the TME [<xref ref-type="bibr" rid="B-087">87</xref>].</p>
          <p>Studies on MSC-based cancer immunotherapy have shown promising results predominantly in preclinical settings, demonstrating their potential to modulate the immune system and enhance anti-tumor responses. MSCs can be used to deliver therapeutic agents directly to tumor sites and modulate the immune system [<xref ref-type="bibr" rid="B-083">83</xref>]. However, unmodified MSCs may also promote immunosuppression, angiogenesis, and tumor progression in certain tumor microenvironments; therefore, their anti-tumor versus pro-tumor effects depend on MSC origin, phenotype, tumor type, and cytokine exposure [<xref ref-type="bibr" rid="B-088">88</xref>].</p>
        </sec>
        <sec id="sec-04-02">
          <label>4.2</label>
          <title>Hematopoietic Stem Cells</title>
          <p>HSCs are multipotent stem cells that give rise to all blood cell types, including immune cells, making them essential for immune system function and reconstitution following damage or disease [<xref ref-type="bibr" rid="B-089">89</xref>]. HSCs are primarily used in hematopoietic stem cell transplantation (HSCT) to restore the immune system in patients with hematological cancers, such as leukemia and lymphoma, where the patient&#x2019;s own immune system has been compromised by disease or treatment [<xref ref-type="bibr" rid="B-090">90</xref>]. HSCT represents an established clinical application of stem cells in oncology, unlike many other stem-cell-based immunomodulatory strategies that remain experimental.</p>
          <p>The immunotherapy potential of HSCs in hematological cancers lies in their ability to reconstitute the immune system and promote tumor rejection, allowing for the establishment of a new, healthy immune system that can target and eliminate cancer cells [<xref ref-type="bibr" rid="B-091">91</xref>]. Allogeneic HSCT, where HSCs are derived from a donor, can induce a graft-versus-tumor (GVT) effect, where donor-derived immune cells recognize and kill tumor cells, providing a potent anti-tumor response [<xref ref-type="bibr" rid="B-092">92</xref>]. HSCs can also be genetically modified to express T-cell receptors (TCRs) or chimeric antigen receptors (CARs) that target tumor-associated antigens, enhancing their ability to recognize and kill cancer cells [<xref ref-type="bibr" rid="B-093">93</xref>].</p>
        </sec>
        <sec id="sec-04-03">
          <label>4.3</label>
          <title>Induced Pluripotent Stem Cells</title>
          <p>Induced pluripotent stem cells (iPSCs) are generated from adult somatic cells through reprogramming, a process that reverses their differentiation and returns them to an embryonic stem cell-like state, capable of differentiating into any cell type in the body [<xref ref-type="bibr" rid="B-094">94</xref>]. iPSCs offer significant potential for personalized therapies, as they can be derived from a patient&#x2019;s own cells, reducing the risk of immune rejection and enabling patient-specific cell therapies [<xref ref-type="bibr" rid="B-095">95</xref>].</p>
          <p>Emerging research on iPSCs in immunotherapy focuses on their potential to generate immune cells with anti-tumor activity, creating a renewable source of immune cells that can be tailored to target specific cancers [<xref ref-type="bibr" rid="B-096">96</xref>]. iPSCs can be differentiated into NK cells, T cells, and DCs that can be used to target and kill cancer cells, offering a versatile platform for developing novel immunotherapies [<xref ref-type="bibr" rid="B-097">97</xref>]. Recent advances in NK-cell expansion, activation, and genetic engineering have further strengthened the potential of stem-cell-derived NK-cell platforms for cancer immunotherapy [<xref ref-type="bibr" rid="B-098">98</xref>]. However, their clinical application remains under investigation. The mechanisms of immune modulation in cancer therapy using iPSCs are still being investigated, but their potential to generate personalized immune cell therapies holds great promise [<xref ref-type="bibr" rid="B-096">96</xref>].</p>
        </sec>
        <sec id="sec-04-04">
          <label>4.4</label>
          <title>Cancer Stem Cells</title>
          <p>CSCs are a subpopulation of tumor cells with stem-like properties that contribute to tumor initiation, progression, and therapeutic resistance, making them a critical target for cancer therapy [<xref ref-type="bibr" rid="B-099">99</xref>]. CSCs can evade immune detection and elimination, contributing to tumor recurrence and metastasis, highlighting the need for strategies to overcome their immune evasion mechanisms [<xref ref-type="bibr" rid="B-100">100</xref>].</p>
          <p>The role of CSCs in immune evasion and therapeutic resistance has garnered significant attention, improving investigations into their interactions with the immune system and the mechanisms by which they escape immune surveillance [<xref ref-type="bibr" rid="B-101">101</xref>]. CSCs can express high levels of immune checkpoint molecules, such as PD-L1, which inhibit T cell activation, preventing T cells from effectively targeting and killing cancer cells [<xref ref-type="bibr" rid="B-102">102</xref>]. They can also secrete factors that suppress immune cell function and promote immune tolerance, creating an immunosuppressive environment that protects them from immune attack [<xref ref-type="bibr" rid="B-103">103</xref>]. Additional mechanisms include reduced antigen presentation, expression of anti-phagocytic molecules such as CD47, and recruitment or activation of immunosuppressive populations including Tregs, MDSCs, and TAMs. These mechanisms can contribute to persistence of CSCs after treatment and thereby promote recurrence and therapeutic resistance [<xref ref-type="bibr" rid="B-023">23</xref>].</p>
          <p>Targeting CSCs has emerged as a promising strategy for cancer therapy, aiming to eliminate the root of the tumor and prevent recurrence and metastasis [<xref ref-type="bibr" rid="B-006">6</xref>]. Strategies include developing drugs that specifically target CSCs, using immunotherapies to target CSC-associated antigens, blocking immune-evasion pathways such as PD-1/PD-L1 and CD47 signaling where appropriate, and modulating the TME to reduce CSC-mediated immune suppression. For instance, 4Mu decreases CD47 expression on hepatic cancer stem cells and primes a potent antitumor T cell response induced by IL-12, demonstrating the potential of targeting CSCs to enhance anti-tumor immunity (<xref ref-type="fig" rid="F-02">Figure 2</xref>) [<xref ref-type="bibr" rid="B-104">104</xref>].</p>
          <fig id="F-02" orientation="portrait" position="float">
            <label>Figure 2</label>
            <caption>
              <p>Cellular sources and pathways relevant to cancer immunomodulation. Somatic cells can be isolated and reprogrammed into induced pluripotent stem cells (iPSCs). Through established, protocol-dependent directed differentiation, iPSCs can generate immune cells, including T cells and macrophages, or differentiate into mesenchymal stem cells (MSCs). MSCs can also be isolated directly for potential therapeutic applications. Hematopoietic stem cells (HSCs) and hematopoietic stem/progenitor cells (HSPCs), obtained through bone marrow aspiration, give rise to immune cells through hematopoietic differentiation. MSCs regulate immune cells through immunomodulation and paracrine signaling rather than direct differentiation into T cells or macrophages. MSC-derived paracrine effects on tumor cells are context-dependent, while immune cells influence tumor cells through immune-mediated mechanisms. Solid arrows indicate activation or differentiation, inhibitory lines indicate suppression, and dashed arrows indicate indirect or context-dependent immunomodulatory effects. Solid arrows labeled &#x201C;Isolation,&#x201D; &#x201C;Bone marrow aspiration,&#x201D; or &#x201C;Reprogramming&#x201D; denote the corresponding procedures; the MSC-to-tumor-cell arrow represents the explicitly labeled context-dependent paracrine effects. Abbreviations: iPSC, induced pluripotent stem cell; MSC, mesenchymal stem cell; HSC, hematopoietic stem cell; HSPC, hematopoietic stem/progenitor cell.</p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure02.jpg"/>
          </fig>
        </sec>
      </sec>
      <sec id="sec-05">
        <label>5.</label>
        <title>Challenges and Limitations</title>
        <sec id="sec-05-01">
          <label>5.1</label>
          <title>Tumor Microenvironment and Immune Evasion</title>
          <p>The TME critically influences the effectiveness of stem cell-based immunomodulation [<xref ref-type="bibr" rid="B-105">105</xref>]. The TME is a complex network of cells, including immune cells, fibroblasts, and endothelial cells,along with extracellular matrix components and soluble factors. The TME can promote tumor growth and metastasis by suppressing anti-tumor immune responses and promoting angiogenesis [<xref ref-type="bibr" rid="B-106">106</xref>]. Immune evasion is a major challenge in cancer therapy. Cancer cells can evade immune detection and elimination through various mechanisms, including the expression of immune checkpoint molecules, the secretion of immunosuppressive factors, and the recruitment of immunosuppressive cells [<xref ref-type="bibr" rid="B-107">107</xref>]. The TME can also contribute to immune evasion by creating a physical barrier that prevents stem cells and stem cell-derived immune cells from reaching tumor cells [<xref ref-type="bibr" rid="B-108">108</xref>].</p>
        </sec>
        <sec id="sec-05-02">
          <label>5.2</label>
          <title>Safety and Ethical Concerns</title>
          <p>The safety of stem cell-based immunotherapies is a major concern [<xref ref-type="bibr" rid="B-109">109</xref>]. Potential risks include tumorigenicity or teratoma formation from residual undifferentiated pluripotent cells, unwanted differentiation, immune rejection, transmission of infectious agents, genomic instability after prolonged culture or genetic manipulation, and potential enhancement of tumor growth by some MSC populations. Immune rejection can occur with allogeneic cells, while infectious-agent transmission remains a risk if cells are not properly screened and handled [<xref ref-type="bibr" rid="B-110">110</xref>]. Long-term safety also remains incompletely defined for many genetically modified or stem-cell-derived therapeutic products.</p>
          <p>Ethical issues surrounding stem cell use in cancer therapy include informed consent, patient selection, and the potential for commercial exploitation. Patients must be fully informed about the potential risks and benefits of stem cell therapy before undergoing treatment. Patient selection criteria must be carefully considered to ensure that patients are likely to benefit from stem cell therapy. The commercialization of stem cell therapy must be carefully regulated to prevent exploitation of vulnerable patients [<xref ref-type="bibr" rid="B-111">111</xref>].</p>
          <p>Recent preclinical and clinical development has attempted to reduce these risks through stringent cell characterization, elimination of residual undifferentiated cells, genomic-stability testing, standardized differentiation and purification procedures, sterility testing, controlled dosing, and long-term follow-up. Gene-engineered cell products may also incorporate safety switches to permit elimination of the administered cells if severe toxicity develops [<xref ref-type="bibr" rid="B-112">112</xref>].</p>
        </sec>
        <sec id="sec-05-03">
          <label>5.3</label>
          <title>Regulatory Issues and Standardization</title>
          <p>Regulatory challenges in stem cell-based cancer therapies include unclear regulatory guidelines and the need for standardized protocols. Stem cell therapies are often classified as biologics, which require rigorous testing and approval processes. However, the regulatory pathways for stem cell therapies are not always clear, leading to delays in the development and approval of new therapies [<xref ref-type="bibr" rid="B-113">113</xref>].</p>
          <p>Standardization of protocols for stem cell isolation and therapy is essential to ensure the reproducibility and reliability of stem-cell-based approaches. Standardized protocols are needed for stem-cell isolation, culture, characterization, and delivery. Use predefined quality-control criteria to assess cell identity, purity, viability, potency, genomic stability, sterility, and batch-to-batch consistency. Manufacturing processes should also control donor or starting-material selection, culture conditions, passage number, cryopreservation, and, when applicable, genetic modification. These requirements are particularly important for clinical-grade products manufactured under Good Manufacturing Practice conditions [<xref ref-type="bibr" rid="B-114">114</xref>].</p>
        </sec>
      </sec>
      <sec id="sec-06">
        <label>6.</label>
        <title>Future Directions and Perspectives</title>
        <p>Genetic modification of stem cells can enhance their immunomodulatory properties and improve therapeutic efficacy. Stem cells can be engineered to express anti-tumor cytokines, deliver oncolytic viruses, or target cancer stem cells [<xref ref-type="bibr" rid="B-115">115</xref>]. For example, CAR T-cells can be engineered for adoptive cell therapy of cancer using long-term episomal gene transfer [<xref ref-type="bibr" rid="B-116">116</xref>].</p>
        <p>Combining stem-cell-based approaches with immune checkpoint inhibitors or CAR-based immune-cell therapies has been proposed as a strategy to improve anti-tumor activity. Potential mechanisms include modulating the immunosuppressive TME, improving delivery of therapeutic molecules, and generating stem-cell-derived immune effector cells. However, most evidence for these combinations remains preclinical, and major barriers include limited cell persistence and tumor infiltration, tumor heterogeneity, immunosuppressive cytokines, manufacturing complexity, and safety concerns [<xref ref-type="bibr" rid="B-117">117</xref>,<xref ref-type="bibr" rid="B-118">118</xref>].</p>
        <p>Recent developments have also expanded the field toward engineered NK-cell therapies and advanced stem-cell-derived experimental models. NK-cell expansion, activation, and genetic engineering are being investigated to improve persistence and tumor cytotoxicity [<xref ref-type="bibr" rid="B-119">119</xref>], while stem-cell-derived organoid systems provide increasingly sophisticated models for studying tissue development, disease, and therapeutic responses [<xref ref-type="bibr" rid="B-098">98</xref>,<xref ref-type="bibr" rid="B-120">120</xref>].</p>
        <p>Tailoring stem-cell-based therapies to individual patient needs and tumor characteristics may improve therapeutic efficacy and reduce side effects. Personalized approaches may involve selecting the most appropriate cellular platform, genetically modifying cells to target specific tumor antigens, and optimizing their delivery to tumor sites [<xref ref-type="bibr" rid="B-121">121</xref>]. However, such personalized strategies remain largely investigational and require validation in prospective clinical studies.</p>
      </sec>
      <sec id="sec-07">
        <label>7.</label>
        <title>Conclusion</title>
        <p>Stem cells and stem-cell-derived products can exert diverse immunomodulatory effects in cancer, influencing immune cells and the TME. These effects include cytokine secretion, modulation of macrophage polarization, and regulation of T-cell responses, particularly in the case of MSCs. However, these effects are highly context-dependent and may either suppress or promote tumor progression. Hematopoietic stem cell transplantation represents an established clinical application for selected hematological malignancies, whereas most MSC-, iPSC-, and engineered stem-cell-based immunotherapeutic approaches remain experimental or in early clinical development. Major challenges include tumorigenicity, unwanted differentiation, genomic instability, immune rejection, manufacturing variability, and uncertain long-term safety. Future studies should therefore focus on clarifying mechanisms, standardizing manufacturing, rigorously evaluating clinical benefit, and identifying patients most likely to benefit from these approaches.</p>
      </sec>
  </body>
  <back>
      <ack>
        <title>Acknowledgments</title>
        <p>All authors declare there is no acknowledgment in this study.</p>
      </ack>
      <notes>
        <title>Author Contributions</title>
        <p>Manal Hadi Ghaffoori Kanaan: conceptualization, supervision, writing &#x2013; original draft, writing &#x2013; review &#x0026; editing; Beom-Jin Lee: conceptualization, investigation, writing &#x2013; original draft, writing &#x2013; review &#x0026; editing; Sura Saad Abdullah: writing &#x2013; original draft, investigation; Chulhun Park: writing &#x2013; review &#x0026; editing; Abdolmajid Ghasemian: writing &#x2013; review &#x0026; editing; Marianne Marianne: writing &#x2013; review &#x0026; editing. All the authors critically revised and approved the final version of the manuscript.</p>
      </notes>
      <notes>
        <title>Funding</title>
        <p>There is no financial support for this study.</p>
      </notes>
      <notes>
        <title>Competing Interests</title>
        <p>The authors declare no competing interests related to this research.</p>
      </notes>
      <notes>
        <title>Data Availability Statement</title>
        <p>Data sharing is not applicable to this article as no new data were created or analyzed in this study.</p>
      </notes>
      <notes>
        <title>AI-Assisted Technologies Statement</title>
        <p>Artificial intelligence (AI) tools were used solely for basic grammar correction and language refinement in the preparation of this manuscript. Specifically, ChatGPT6.1 was employed to improve the readability and linguistic clarity of the English text. All scientific content, data interpretation, and conclusions were developed independently by the author. The authors have thoroughly reviewed and edited the AI-assisted text to ensure its accuracy and accept full responsibility for the content of the manuscript.</p>
      </notes>
      <ref-list>
        <title>References</title>
        <ref id="B-001">
          <label>1. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Zakrzewski</surname><given-names>W</given-names></name>,
            <name><surname>Dobrzy&#x0144;ski</surname><given-names>M</given-names></name>,
            <name><surname>Szymonowicz</surname><given-names>M</given-names></name>,
            <name><surname>Rybak</surname><given-names>Z</given-names></name>.
            <article-title>Stem cells: Past, present, and future</article-title>.
            <source>Stem Cell Res Ther</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>10</volume>:
            <fpage>68</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-002">
          <label>2. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Alatyyat</surname><given-names>SM</given-names></name>,
            <name><surname>Alasmari</surname><given-names>HM</given-names></name>,
            <name><surname>Aleid</surname><given-names>OA</given-names></name>,
            <name><surname>Abdel-Maksoud</surname><given-names>MS</given-names></name>,
            <name><surname>Elsherbiny</surname><given-names>N</given-names></name>.
            <article-title>Umbilical cord stem cells: Background, processing and applications</article-title>.
            <source>Tissue Cell</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>65</volume>:
            <fpage>101351</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-003">
          <label>3. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Yamanaka</surname><given-names>S</given-names></name>.
            <article-title>Pluripotent stem cell-based cell therapy-promise and challenges</article-title>.
            <source>Cell Stem Cell</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>27</volume>:
            <fpage>523</fpage>-<lpage>531</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-004">
          <label>4. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Mazini</surname><given-names>L</given-names></name>,
            <name><surname>Rochette</surname><given-names>L</given-names></name>,
            <name><surname>Admou</surname><given-names>B</given-names></name>,
            <name><surname>Amal</surname><given-names>S</given-names></name>,
            <name><surname>Malka</surname><given-names>G</given-names></name>.
            <article-title>Hopes and limits of adipose-derived stem cells (ADSCs) and mesenchymal stem cells (MSCs) in wound healing</article-title>.
            <source>Int J Mol Sci</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>21</volume>:
            <fpage>1306</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-005">
          <label>5. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Lee</surname><given-names>SJ</given-names></name>,
            <name><surname>Jung</surname><given-names>C</given-names></name>,
            <name><surname>Oh</surname><given-names>JE</given-names></name>,
            <name><surname>Kim</surname><given-names>S</given-names></name>,
            <name><surname>Lee</surname><given-names>S</given-names></name>,
            <name><surname>Lee</surname><given-names>JY</given-names></name>,
            <etal/>.
            <article-title>Generation of red blood cells from human pluripotent stem cells-An update</article-title>.
            <source>Cells</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>12</volume>:
            <fpage>1554</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-006">
          <label>6. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Biserova</surname><given-names>K</given-names></name>,
            <name><surname>Jakovlevs</surname><given-names>A</given-names></name>,
            <name><surname>Uljanovs</surname><given-names>R</given-names></name>,
            <name><surname>Strumfa</surname><given-names>I</given-names></name>.
            <article-title>Cancer stem cells: Significance in origin, pathogenesis and treatment of glioblastoma</article-title>.
            <source>Cells</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>10</volume>:
            <fpage>621</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-007">
          <label>7. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Y&#x0131;lmaz</surname><given-names>M</given-names></name>,
            <name><surname>Kaplan</surname><given-names>F</given-names></name>,
            <name><surname>Mender</surname><given-names>I</given-names></name>,
            <name><surname>Gryaznov</surname><given-names>SM</given-names></name>,
            <name><surname>Dikmen</surname><given-names>ZG</given-names></name>.
            <article-title>Cancer stem cells and anti-tumor immunity</article-title>.
            <source>Curr Stem Cell Res Ther</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>18</volume>:
            <fpage>445</fpage>-<lpage>459</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-008">
          <label>8. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Kode</surname><given-names>JA</given-names></name>,
            <name><surname>Mukherjee</surname><given-names>S</given-names></name>,
            <name><surname>Joglekar</surname><given-names>MV</given-names></name>,
            <name><surname>Hardikar</surname><given-names>AA</given-names></name>.
            <article-title>Mesenchymal stem cells: Immunobiology and role in immunomodulation and tissue regeneration</article-title>.
            <source>Cytotherapy</source>.
            <year iso-8601-date="2009">2009</year>;
            <volume>11</volume>:
            <fpage>377</fpage>-<lpage>391</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-009">
          <label>9. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Al-Ghadban</surname><given-names>S</given-names></name>,
            <name><surname>Bunnell</surname><given-names>BA</given-names></name>.
            <article-title>Adipose tissue-derived stem cells: Immunomodulatory effects and therapeutic potential</article-title>.
            <source>Physiology</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>35</volume>:
            <fpage>125</fpage>-<lpage>133</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-010">
          <label>10. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Najar</surname><given-names>M</given-names></name>,
            <name><surname>Raicevic</surname><given-names>G</given-names></name>,
            <name><surname>Fayyad-Kazan</surname><given-names>H</given-names></name>,
            <name><surname>Bron</surname><given-names>D</given-names></name>,
            <name><surname>Toungouz</surname><given-names>M</given-names></name>,
            <name><surname>Lagneaux</surname><given-names>L</given-names></name>.
            <article-title>Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells</article-title>.
            <source>Cytotherapy</source>.
            <year iso-8601-date="2016">2016</year>;
            <volume>18</volume>:
            <fpage>160</fpage>-<lpage>171</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-011">
          <label>11. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Chuang</surname><given-names>YM</given-names></name>,
            <name><surname>Tzeng</surname><given-names>SF</given-names></name>,
            <name><surname>Ho</surname><given-names>PC</given-names></name>,
            <name><surname>Tsai</surname><given-names>CH</given-names></name>.
            <article-title>Immunosurveillance encounters cancer metabolism</article-title>.
            <source>EMBO Rep</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>25</volume>:
            <fpage>471</fpage>-<lpage>488</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-012">
          <label>12. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Kunimasa</surname><given-names>K</given-names></name>,
            <name><surname>Goto</surname><given-names>T</given-names></name>.
            <article-title>Immunosurveillance and immunoediting of lung cancer: Current perspectives and challenges</article-title>.
            <source>Int J Mol Sci</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>21</volume>:
            <fpage>597</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-013">
          <label>13. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Gopalakrishnan</surname><given-names>V</given-names></name>,
            <name><surname>Helmink</surname><given-names>BA</given-names></name>,
            <name><surname>Spencer</surname><given-names>CN</given-names></name>,
            <name><surname>Reuben</surname><given-names>A</given-names></name>,
            <name><surname>Wargo</surname><given-names>JA</given-names></name>.
            <article-title>The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy</article-title>.
            <source>Cancer Cell</source>.
            <year iso-8601-date="2018">2018</year>;
            <volume>33</volume>:
            <fpage>570</fpage>-<lpage>580</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-014">
          <label>14. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wang</surname><given-names>C</given-names></name>,
            <name><surname>Barnoud</surname><given-names>C</given-names></name>,
            <name><surname>Cenerenti</surname><given-names>M</given-names></name>,
            <name><surname>Sun</surname><given-names>M</given-names></name>,
            <name><surname>Caffa</surname><given-names>I</given-names></name>,
            <name><surname>Kizil</surname><given-names>B</given-names></name>,
            <etal/>.
            <article-title>Dendritic cells direct circadian anti-tumour immune responses</article-title>.
            <source>Nature</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>614</volume>:
            <fpage>136</fpage>-<lpage>143</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-015">
          <label>15. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Ma</surname><given-names>P</given-names></name>,
            <name><surname>Beatty</surname><given-names>PL</given-names></name>,
            <name><surname>McKolanis</surname><given-names>J</given-names></name>,
            <name><surname>Brand</surname><given-names>R</given-names></name>,
            <name><surname>Schoen</surname><given-names>RE</given-names></name>,
            <name><surname>Finn</surname><given-names>OJ</given-names></name>.
            <article-title>Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignancy share phenotypic and functional characteristics with MDSC in cancer</article-title>.
            <source>Front Immunol</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>10</volume>:
            <fpage>1401</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-016">
          <label>16. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Rezaie</surname><given-names>J</given-names></name>,
            <name><surname>Chodari</surname><given-names>L</given-names></name>,
            <name><surname>Mohammadpour-Asl</surname><given-names>S</given-names></name>,
            <name><surname>Jafari</surname><given-names>A</given-names></name>,
            <name><surname>Niknam</surname><given-names>Z</given-names></name>.
            <article-title>Cell-mediated barriers in cancer immunosurveillance</article-title>.
            <source>Life Sci</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>342</volume>:
            <fpage>122528</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-017">
          <label>17. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Smyth</surname><given-names>MJ</given-names></name>,
            <name><surname>Dunn</surname><given-names>GP</given-names></name>,
            <name><surname>Schreiber</surname><given-names>RD</given-names></name>.
            <article-title>Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity</article-title>.
            <source>Adv Immunol</source>.
            <year iso-8601-date="2006">2006</year>;
            <volume>90</volume>:
            <fpage>1</fpage>-<lpage>50</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-018">
          <label>18. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Liu</surname><given-names>N</given-names></name>,
            <name><surname>Xiao</surname><given-names>X</given-names></name>,
            <name><surname>Zhang</surname><given-names>Z</given-names></name>,
            <name><surname>Mao</surname><given-names>C</given-names></name>,
            <name><surname>Wan</surname><given-names>M</given-names></name>,
            <name><surname>Shen</surname><given-names>J</given-names></name>.
            <article-title>Advances in cancer vaccine research</article-title>.
            <source>ACS Biomater Sci Eng</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>9</volume>:
            <fpage>5999</fpage>-<lpage>6023</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-019">
          <label>19. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wang</surname><given-names>F</given-names></name>,
            <name><surname>Cheng</surname><given-names>F</given-names></name>,
            <name><surname>Zheng</surname><given-names>F</given-names></name>.
            <article-title>Stem cell like memory T cells: A new paradigm in cancer immunotherapy</article-title>.
            <source>Clin Immunol</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>241</volume>:
            <fpage>109078</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-020">
          <label>20. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wu</surname><given-names>R</given-names></name>,
            <name><surname>Fan</surname><given-names>X</given-names></name>,
            <name><surname>Wang</surname><given-names>Y</given-names></name>,
            <name><surname>Shen</surname><given-names>M</given-names></name>,
            <name><surname>Zheng</surname><given-names>Y</given-names></name>,
            <name><surname>Zhao</surname><given-names>S</given-names></name>,
            <etal/>.
            <article-title>Mesenchymal stem cell-derived extracellular vesicles in liver immunity and therapy</article-title>.
            <source>Front Immunol</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>13</volume>:
            <fpage>833878</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-021">
          <label>21. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Yuan</surname><given-names>H</given-names></name>,
            <name><surname>Li</surname><given-names>S</given-names></name>,
            <name><surname>Zhao</surname><given-names>Z</given-names></name>,
            <name><surname>Wang</surname><given-names>Y</given-names></name>.
            <article-title>Regulation of interferon-&#x03B2;-modified human umbilical cord mesenchymal stem cell-derived exosomes in proliferation and apoptosis of prostate cancer cells</article-title>.
            <source>Organogenesis</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>19</volume>:
            <fpage>2285836</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-022">
          <label>22. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Dehnavi</surname><given-names>S</given-names></name>,
            <name><surname>Dadmanesh</surname><given-names>M</given-names></name>,
            <name><surname>Rouzbahani</surname><given-names>NH</given-names></name>,
            <name><surname>Karimi</surname><given-names>M</given-names></name>,
            <name><surname>Asadirad</surname><given-names>A</given-names></name>,
            <name><surname>Gholami</surname><given-names>M</given-names></name>,
            <etal/>.
            <article-title>Mesenchymal stem cell-derived exosome: An interesting nanocarrier to improve allergen-specific intranasal immunotherapy</article-title>.
            <source>Iran J Allergy Asthma Immunol</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>22</volume>:
            <fpage>561</fpage>-<lpage>574</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-023">
          <label>23. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Pu</surname><given-names>Y</given-names></name>,
            <name><surname>Ji</surname><given-names>Q</given-names></name>.
            <article-title>Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression</article-title>.
            <source>Front Immunol</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>13</volume>:
            <fpage>874589</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-024">
          <label>24. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Miao</surname><given-names>L</given-names></name>,
            <name><surname>Qi</surname><given-names>J</given-names></name>,
            <name><surname>Zhao</surname><given-names>QI</given-names></name>,
            <name><surname>Wu</surname><given-names>QN</given-names></name>,
            <name><surname>Wei</surname><given-names>DL</given-names></name>,
            <name><surname>Wei</surname><given-names>XL</given-names></name>,
            <etal/>.
            <article-title>Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells</article-title>.
            <source>Theranostics</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>10</volume>:
            <fpage>498</fpage>-<lpage>515</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-025">
          <label>25. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Elliott</surname><given-names>SL</given-names></name>,
            <name><surname>Kose</surname><given-names>E</given-names></name>,
            <name><surname>Lewis</surname><given-names>AL</given-names></name>,
            <name><surname>Steinfeld</surname><given-names>AE</given-names></name>,
            <name><surname>Zollinger</surname><given-names>EA</given-names></name>.
            <article-title>Modeling the stem cell hypothesis: Investigating the effects of cancer stem cells and TGF-&#x03B2; on tumor growth</article-title>.
            <source>Math Biosci Eng</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>16</volume>:
            <fpage>7177</fpage>-<lpage>7194</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-026">
          <label>26. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Nazari</surname><given-names>F</given-names></name>,
            <name><surname>Pearson</surname><given-names>AT</given-names></name>,
            <name><surname>N&#x00F6;r</surname><given-names>JE</given-names></name>,
            <name><surname>Jackson</surname><given-names>TL</given-names></name>.
            <article-title>A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment</article-title>.
            <source>PLoS Comput Biol</source>.
            <year iso-8601-date="2018">2018</year>;
            <volume>14</volume>:
            <fpage>e1005920</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-027">
          <label>27. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Chanmee</surname><given-names>T</given-names></name>,
            <name><surname>Ontong</surname><given-names>P</given-names></name>,
            <name><surname>Mochizuki</surname><given-names>N</given-names></name>,
            <name><surname>Kongtawelert</surname><given-names>P</given-names></name>,
            <name><surname>Konno</surname><given-names>K</given-names></name>,
            <name><surname>Itano</surname><given-names>N</given-names></name>.
            <article-title>Excessive hyaluronan production promotes acquisition of cancer stem cell signatures through the coordinated regulation of Twist and the transforming growth factor &#x03B2; (TGF-&#x03B2;)-Snail signaling axis</article-title>.
            <source>J Biol Chem</source>.
            <year iso-8601-date="2014">2014</year>;
            <volume>289</volume>:
            <fpage>26038</fpage>-<lpage>26056</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-028">
          <label>28. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Arabpour</surname><given-names>M</given-names></name>,
            <name><surname>Saghazadeh</surname><given-names>A</given-names></name>,
            <name><surname>Rezaei</surname><given-names>N</given-names></name>.
            <article-title>Anti-inflammatory and M2 macrophage polarization-promoting effect of mesenchymal stem cell-derived exosomes</article-title>.
            <source>Int Immunopharmacol</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>97</volume>:
            <fpage>107823</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-029">
          <label>29. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Yang</surname><given-names>L</given-names></name>,
            <name><surname>Shi</surname><given-names>P</given-names></name>,
            <name><surname>Zhao</surname><given-names>G</given-names></name>,
            <name><surname>Xu</surname><given-names>J</given-names></name>,
            <name><surname>Peng</surname><given-names>W</given-names></name>,
            <name><surname>Zhang</surname><given-names>J</given-names></name>,
            <etal/>.
            <article-title>Targeting cancer stem cell pathways for cancer therapy</article-title>.
            <source>Signal Transduct Target Ther</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>5</volume>:
            <fpage>8</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-030">
          <label>30. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Yu</surname><given-names>PC</given-names></name>,
            <name><surname>Liu</surname><given-names>D</given-names></name>,
            <name><surname>Han</surname><given-names>ZX</given-names></name>,
            <name><surname>Liang</surname><given-names>F</given-names></name>,
            <name><surname>Hao</surname><given-names>CY</given-names></name>,
            <name><surname>Lei</surname><given-names>YT</given-names></name>,
            <etal/>.
            <article-title>Thymopentin-mediated inhibition of cancer stem cell stemness enhances the cytotoxic effect of oxaliplatin on colon cancer cells</article-title>.
            <source>Front Pharmacol</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>13</volume>:
            <fpage>779715</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-031">
          <label>31. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Casbon</surname><given-names>AJ</given-names></name>,
            <name><surname>Reynaud</surname><given-names>D</given-names></name>,
            <name><surname>Park</surname><given-names>C</given-names></name>,
            <name><surname>Khuc</surname><given-names>E</given-names></name>,
            <name><surname>Gan</surname><given-names>DD</given-names></name>,
            <name><surname>Schepers</surname><given-names>K</given-names></name>,
            <etal/>.
            <article-title>Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils</article-title>.
            <source>Proc Natl Acad Sci</source>.
            <year iso-8601-date="2015">2015</year>;
            <volume>112</volume>:
            <fpage>E566</fpage>-<lpage>E575</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-032">
          <label>32. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Pont</surname><given-names>MJ</given-names></name>,
            <name><surname>Honders</surname><given-names>MW</given-names></name>,
            <name><surname>Kremer</surname><given-names>AN</given-names></name>,
            <name><surname>van Kooten</surname><given-names>C</given-names></name>,
            <name><surname>Out</surname><given-names>C</given-names></name>,
            <name><surname>Hiemstra</surname><given-names>PS</given-names></name>,
            <etal/>.
            <article-title>Microarray gene expression analysis to evaluate cell type specific expression of targets relevant for immunotherapy of hematological malignancies</article-title>.
            <source>PLoS One</source>.
            <year iso-8601-date="2016">2016</year>;
            <volume>11</volume>:
            <fpage>e0155165</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-033">
          <label>33. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Di Lullo</surname><given-names>G</given-names></name>,
            <name><surname>Marcatti</surname><given-names>M</given-names></name>,
            <name><surname>Heltai</surname><given-names>S</given-names></name>,
            <name><surname>Tresoldi</surname><given-names>C</given-names></name>,
            <name><surname>Paganoni</surname><given-names>AM</given-names></name>,
            <name><surname>Bordignon</surname><given-names>C</given-names></name>,
            <etal/>.
            <article-title>Immunomodulatory drugs in the context of autologous hematopoietic stem cell transplantation associate with reduced pro-tumor T cell subsets in multiple myeloma</article-title>.
            <source>Front Immunol</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>9</volume>:
            <fpage>3171</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-034">
          <label>34. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Al Sayed</surname><given-names>MF</given-names></name>,
            <name><surname>Amrein</surname><given-names>MA</given-names></name>,
            <name><surname>B&#x00FC;hrer</surname><given-names>ED</given-names></name>,
            <name><surname>Huguenin</surname><given-names>AL</given-names></name>,
            <name><surname>Radpour</surname><given-names>R</given-names></name>,
            <name><surname>Riether</surname><given-names>C</given-names></name>,
            <etal/>.
            <article-title>T-cell&#x2013;secreted TNF&#x03B1; induces emergency myelopoiesis and myeloid-derived suppressor cell differentiation in cancer</article-title>.
            <source>Cancer Res</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>79</volume>:
            <fpage>346</fpage>-<lpage>359</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-035">
          <label>35. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Lee</surname><given-names>SW</given-names></name>,
            <name><surname>Lee</surname><given-names>H</given-names></name>,
            <name><surname>Lee</surname><given-names>KW</given-names></name>,
            <name><surname>Kim</surname><given-names>MJ</given-names></name>,
            <name><surname>Kang</surname><given-names>SW</given-names></name>,
            <name><surname>Lee</surname><given-names>YJ</given-names></name>,
            <etal/>.
            <article-title>CD8&#x03B1;+ dendritic cells potentiate antitumor and immune activities against murine ovarian cancers</article-title>.
            <source>Sci Rep</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>13</volume>:
            <fpage>98</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-036">
          <label>36. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Rossnagl</surname><given-names>S</given-names></name>,
            <name><surname>Altrock</surname><given-names>E</given-names></name>,
            <name><surname>Sens</surname><given-names>C</given-names></name>,
            <name><surname>Kraft</surname><given-names>S</given-names></name>,
            <name><surname>Rau</surname><given-names>K</given-names></name>,
            <name><surname>Milsom</surname><given-names>MD</given-names></name>,
            <etal/>.
            <article-title>EDA-fibronectin originating from osteoblasts inhibits the immune response against cancer</article-title>.
            <source>PLoS Biol</source>.
            <year iso-8601-date="2016">2016</year>;
            <volume>14</volume>:
            <fpage>e1002562</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-037">
          <label>37. </label>
          <mixed-citation publication-type="journal">
            <name><surname>de Witte</surname><given-names>SF</given-names></name>,
            <name><surname>Luk</surname><given-names>F</given-names></name>,
            <name><surname>Sierra Parraga</surname><given-names>JM</given-names></name>,
            <name><surname>Gargesha</surname><given-names>M</given-names></name>,
            <name><surname>Merino</surname><given-names>A</given-names></name>,
            <name><surname>Korevaar</surname><given-names>SS</given-names></name>,
            <etal/>.
            <article-title>Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells</article-title>.
            <source>Stem Cells</source>.
            <year iso-8601-date="2018">2018</year>;
            <volume>36</volume>:
            <fpage>602</fpage>-<lpage>615</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-038">
          <label>38. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wellhausen</surname><given-names>N</given-names></name>,
            <name><surname>O&#x2019;Connell</surname><given-names>RP</given-names></name>,
            <name><surname>Lesch</surname><given-names>S</given-names></name>,
            <name><surname>Engel</surname><given-names>NW</given-names></name>,
            <name><surname>Rennels</surname><given-names>AK</given-names></name>,
            <name><surname>Gonzales</surname><given-names>D</given-names></name>,
            <etal/>.
            <article-title>Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy</article-title>.
            <source>Sci Transl Med</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>15</volume>:
            <fpage>eadi1145</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-039">
          <label>39. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Rueff</surname><given-names>J</given-names></name>,
            <name><surname>Medinger</surname><given-names>M</given-names></name>,
            <name><surname>Heim</surname><given-names>D</given-names></name>,
            <name><surname>Passweg</surname><given-names>J</given-names></name>,
            <name><surname>Stern</surname><given-names>M</given-names></name>.
            <article-title>Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma</article-title>.
            <source>Biol Blood Marrow Transplant</source>.
            <year iso-8601-date="2014">2014</year>;
            <volume>20</volume>:
            <fpage>896</fpage>-<lpage>899</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-040">
          <label>40. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Zhang</surname><given-names>L</given-names></name>,
            <name><surname>Tang</surname><given-names>A</given-names></name>,
            <name><surname>Zhou</surname><given-names>Y</given-names></name>,
            <name><surname>Tang</surname><given-names>J</given-names></name>,
            <name><surname>Luo</surname><given-names>Z</given-names></name>,
            <name><surname>Jiang</surname><given-names>C</given-names></name>,
            <etal/>.
            <article-title>Tumor-conditioned mesenchymal stem cells display hematopoietic differentiation and diminished influx of Ca<sup>2+</sup></article-title>.
            <source>Stem Cells Dev</source>.
            <year iso-8601-date="2012">2012</year>;
            <volume>21</volume>:
            <fpage>1418</fpage>-<lpage>1428</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-041">
          <label>41. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Giles</surname><given-names>AJ</given-names></name>,
            <name><surname>Reid</surname><given-names>CM</given-names></name>,
            <name><surname>Evans</surname><given-names>JD</given-names></name>,
            <name><surname>Murgai</surname><given-names>M</given-names></name>,
            <name><surname>Vicioso</surname><given-names>Y</given-names></name>,
            <name><surname>Highfill</surname><given-names>SL</given-names></name>,
            <etal/>.
            <article-title>Activation of hematopoietic stem/progenitor cells promotes immunosuppression within the pre-metastatic niche</article-title>.
            <source>Cancer Res</source>.
            <year iso-8601-date="2016">2016</year>;
            <volume>76</volume>:
            <fpage>1335</fpage>-<lpage>1347</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-042">
          <label>42. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wu</surname><given-names>WC</given-names></name>,
            <name><surname>Sun</surname><given-names>HW</given-names></name>,
            <name><surname>Chen</surname><given-names>HT</given-names></name>,
            <name><surname>Liang</surname><given-names>J</given-names></name>,
            <name><surname>Yu</surname><given-names>XJ</given-names></name>,
            <name><surname>Wu</surname><given-names>C</given-names></name>,
            <etal/>.
            <article-title>Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients</article-title>.
            <source>Proc Natl Acad Sci</source>.
            <year iso-8601-date="2014">2014</year>;
            <volume>111</volume>:
            <fpage>4221</fpage>-<lpage>4226</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-043">
          <label>43. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Markopoulos</surname><given-names>GS</given-names></name>,
            <name><surname>Roupakia</surname><given-names>E</given-names></name>,
            <name><surname>Marcu</surname><given-names>KB</given-names></name>,
            <name><surname>Kolettas</surname><given-names>E</given-names></name>.
            <article-title>Epigenetic regulation of inflammatory cytokine-induced epithelial-to-mesenchymal cell transition and cancer stem cell generation</article-title>.
            <source>Cells</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>8</volume>:
            <fpage>1143</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-044">
          <label>44. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Kuo</surname><given-names>MH</given-names></name>,
            <name><surname>Chen</surname><given-names>PY</given-names></name>,
            <name><surname>Yang</surname><given-names>YP</given-names></name>,
            <name><surname>Zheng</surname><given-names>MY</given-names></name>,
            <name><surname>Miao</surname><given-names>CC</given-names></name>,
            <name><surname>Wen</surname><given-names>KC</given-names></name>,
            <etal/>.
            <article-title>Cytokine and epigenetic regulation of programmed death-ligand 1 in stem cell differentiation and cancer cell plasticity</article-title>.
            <source>Stem Cells</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>39</volume>:
            <fpage>1298</fpage>-<lpage>1309</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-045">
          <label>45. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Radharani</surname><given-names>NN</given-names></name>,
            <name><surname>Yadav</surname><given-names>AS</given-names></name>,
            <name><surname>Nimma</surname><given-names>R</given-names></name>,
            <name><surname>Kumar</surname><given-names>TS</given-names></name>,
            <name><surname>Bulbule</surname><given-names>A</given-names></name>,
            <name><surname>Chanukuppa</surname><given-names>V</given-names></name>,
            <etal/>.
            <article-title>Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway</article-title>.
            <source>Cancer Cell Int</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>22</volume>:
            <fpage>122</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-046">
          <label>46. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Ibrahim</surname><given-names>SA</given-names></name>,
            <name><surname>Gadalla</surname><given-names>R</given-names></name>,
            <name><surname>El-Ghonaimy</surname><given-names>EA</given-names></name>,
            <name><surname>Samir</surname><given-names>O</given-names></name>,
            <name><surname>Mohamed</surname><given-names>HT</given-names></name>,
            <name><surname>Hassan</surname><given-names>H</given-names></name>,
            <etal/>.
            <article-title>Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways</article-title>.
            <source>Mol Cancer</source>.
            <year iso-8601-date="2017">2017</year>;
            <volume>16</volume>:
            <fpage>57</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-047">
          <label>47. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wang</surname><given-names>J</given-names></name>,
            <name><surname>Wang</surname><given-names>Y</given-names></name>,
            <name><surname>Wang</surname><given-names>S</given-names></name>,
            <name><surname>Cai</surname><given-names>J</given-names></name>,
            <name><surname>Shi</surname><given-names>J</given-names></name>,
            <name><surname>Sui</surname><given-names>X</given-names></name>,
            <etal/>.
            <article-title>Bone marrow-derived mesenchymal stem cell-secreted IL-8 promotes the angiogenesis and growth of colorectal cancer</article-title>.
            <source>Oncotarget</source>.
            <year iso-8601-date="2015">2015</year>;
            <volume>6</volume>:
            <fpage>42825</fpage>-<lpage>42837</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-048">
          <label>48. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Patel</surname><given-names>SA</given-names></name>,
            <name><surname>Meyer</surname><given-names>JR</given-names></name>,
            <name><surname>Greco</surname><given-names>SJ</given-names></name>,
            <name><surname>Corcoran</surname><given-names>KE</given-names></name>,
            <name><surname>Bryan</surname><given-names>M</given-names></name>,
            <name><surname>Rameshwar</surname><given-names>P</given-names></name>.
            <article-title>Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-&#x03B2;</article-title>.
            <source>J Immunol</source>.
            <year iso-8601-date="2010">2010</year>;
            <volume>184</volume>:
            <fpage>5885</fpage>-<lpage>5894</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-049">
          <label>49. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Pakravan</surname><given-names>K</given-names></name>,
            <name><surname>Babashah</surname><given-names>S</given-names></name>,
            <name><surname>Sadeghizadeh</surname><given-names>M</given-names></name>,
            <name><surname>Mowla</surname><given-names>SJ</given-names></name>,
            <name><surname>Mossahebi-Mohammadi</surname><given-names>M</given-names></name>,
            <name><surname>Ataei</surname><given-names>F</given-names></name>,
            <etal/>.
            <article-title>MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1&#x03B1;/VEGF signaling axis in breast cancer cells</article-title>.
            <source>Cell Oncol</source>.
            <year iso-8601-date="2017">2017</year>;
            <volume>40</volume>:
            <fpage>457</fpage>-<lpage>470</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-050">
          <label>50. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wu</surname><given-names>M</given-names></name>,
            <name><surname>Chen</surname><given-names>L</given-names></name>,
            <name><surname>Qi</surname><given-names>Y</given-names></name>,
            <name><surname>Ci</surname><given-names>H</given-names></name>,
            <name><surname>Mou</surname><given-names>S</given-names></name>,
            <name><surname>Yang</surname><given-names>J</given-names></name>,
            <etal/>.
            <article-title>Human umbilical cord mesenchymal stem cell promotes angiogenesis via integrin &#x03B2;1/ERK1/2/HIF-1&#x03B1;/VEGF-A signaling pathway for off-the-shelf breast tissue engineering</article-title>.
            <source>Stem Cell Res Ther</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>13</volume>:
            <fpage>99</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-051">
          <label>51. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Yazdani</surname><given-names>Y</given-names></name>,
            <name><surname>Rad</surname><given-names>MR</given-names></name>,
            <name><surname>Taghipour</surname><given-names>M</given-names></name>,
            <name><surname>Chenari</surname><given-names>N</given-names></name>,
            <name><surname>Ghaderi</surname><given-names>A</given-names></name>,
            <name><surname>Razmkhah</surname><given-names>M</given-names></name>.
            <article-title>Genistein suppression of matrix metalloproteinase 2 (MMP-2) and vascular endothelial growth factor (VEGF) expression in mesenchymal stem cell like cells isolated from high and low grade gliomas</article-title>.
            <source>Asian Pac J Cancer Prev</source>.
            <year iso-8601-date="2016">2016</year>;
            <volume>17</volume>:
            <fpage>5303</fpage>-<lpage>5307</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-052">
          <label>52. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Kalamegam</surname><given-names>G</given-names></name>,
            <name><surname>Sait</surname><given-names>KH</given-names></name>,
            <name><surname>Anfinan</surname><given-names>N</given-names></name>,
            <name><surname>Kadam</surname><given-names>R</given-names></name>,
            <name><surname>Ahmed</surname><given-names>F</given-names></name>,
            <name><surname>Rasool</surname><given-names>M</given-names></name>,
            <etal/>.
            <article-title>Cytokines secreted by human Wharton&#x2019;s jelly stem cells inhibit the proliferation of ovarian cancer (OVCAR3) cells in vitro</article-title>.
            <source>Oncol Lett</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>17</volume>:
            <fpage>4521</fpage>-<lpage>4531</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-053">
          <label>53. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Osman</surname><given-names>A</given-names></name>,
            <name><surname>Oze</surname><given-names>M</given-names></name>,
            <name><surname>Afify</surname><given-names>SM</given-names></name>,
            <name><surname>Hassan</surname><given-names>G</given-names></name>,
            <name><surname>El-Ghlban</surname><given-names>S</given-names></name>,
            <name><surname>Nawara</surname><given-names>HM</given-names></name>,
            <etal/>.
            <article-title>Tumor-associated macrophages derived from cancer stem cells</article-title>.
            <source>Acta Histochem</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>122</volume>:
            <fpage>151628</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-054">
          <label>54. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Li</surname><given-names>D</given-names></name>,
            <name><surname>Zhang</surname><given-names>Q</given-names></name>,
            <name><surname>Li</surname><given-names>L</given-names></name>,
            <name><surname>Chen</surname><given-names>K</given-names></name>,
            <name><surname>Yang</surname><given-names>J</given-names></name>,
            <name><surname>Dixit</surname><given-names>D</given-names></name>,
            <etal/>.
            <article-title>&#x03B2;2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages</article-title>.
            <source>Cancer Res</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>82</volume>:
            <fpage>3321</fpage>-<lpage>3334</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-055">
          <label>55. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Luo</surname><given-names>S</given-names></name>,
            <name><surname>Yang</surname><given-names>G</given-names></name>,
            <name><surname>Ye</surname><given-names>P</given-names></name>,
            <name><surname>Cao</surname><given-names>N</given-names></name>,
            <name><surname>Chi</surname><given-names>X</given-names></name>,
            <name><surname>Yang</surname><given-names>WH</given-names></name>,
            <etal/>.
            <article-title>Macrophages are a double-edged sword: Molecular crosstalk between tumor-associated macrophages and cancer stem cells</article-title>.
            <source>Biomolecules</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>12</volume>:
            <fpage>850</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-056">
          <label>56. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Jafarzadeh</surname><given-names>N</given-names></name>,
            <name><surname>Safari</surname><given-names>Z</given-names></name>,
            <name><surname>Pornour</surname><given-names>M</given-names></name>,
            <name><surname>Amirizadeh</surname><given-names>N</given-names></name>,
            <name><surname>Forouzandeh Moghadam</surname><given-names>M</given-names></name>,
            <name><surname>Sadeghizadeh</surname><given-names>M</given-names></name>.
            <article-title>Alteration of cellular and immune&#x2010;related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomes</article-title>.
            <source>J Cell Physiol</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>234</volume>:
            <fpage>3697</fpage>-<lpage>3710</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-057">
          <label>57. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wolfe</surname><given-names>AR</given-names></name>,
            <name><surname>Trenton</surname><given-names>NJ</given-names></name>,
            <name><surname>Debeb</surname><given-names>BG</given-names></name>,
            <name><surname>Larson</surname><given-names>R</given-names></name>,
            <name><surname>Ruffell</surname><given-names>B</given-names></name>,
            <name><surname>Chu</surname><given-names>K</given-names></name>,
            <etal/>.
            <article-title>Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models</article-title>.
            <source>Oncotarget</source>.
            <year iso-8601-date="2016">2016</year>;
            <volume>7</volume>:
            <fpage>82482</fpage>-<lpage>82492</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-058">
          <label>58. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Sun</surname><given-names>W</given-names></name>,
            <name><surname>Yan</surname><given-names>S</given-names></name>,
            <name><surname>Yang</surname><given-names>C</given-names></name>,
            <name><surname>Yang</surname><given-names>J</given-names></name>,
            <name><surname>Wang</surname><given-names>H</given-names></name>,
            <name><surname>Li</surname><given-names>C</given-names></name>,
            <etal/>.
            <article-title>Mesenchymal stem cells-derived exosomes ameliorate lupus by inducing M2 macrophage polarization and regulatory T cell expansion in MRL/lpr mice</article-title>.
            <source>Immunol Invest</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>51</volume>:
            <fpage>1785</fpage>-<lpage>1803</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-059">
          <label>59. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Liu</surname><given-names>X</given-names></name>,
            <name><surname>Zhang</surname><given-names>M</given-names></name>,
            <name><surname>Liu</surname><given-names>H</given-names></name>,
            <name><surname>Zhu</surname><given-names>R</given-names></name>,
            <name><surname>He</surname><given-names>H</given-names></name>,
            <name><surname>Zhou</surname><given-names>Y</given-names></name>,
            <etal/>.
            <article-title>Bone marrow mesenchymal stem cell-derived exosomes attenuate cerebral ischemia-reperfusion injury-induced neuroinflammation and pyroptosis by modulating microglia M1/M2 phenotypes</article-title>.
            <source>Exp Neurol</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>341</volume>:
            <fpage>113700</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-060">
          <label>60. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Weng</surname><given-names>YS</given-names></name>,
            <name><surname>Tseng</surname><given-names>HY</given-names></name>,
            <name><surname>Chen</surname><given-names>YA</given-names></name>,
            <name><surname>Shen</surname><given-names>PC</given-names></name>,
            <name><surname>Al Haq</surname><given-names>AT</given-names></name>,
            <name><surname>Chen</surname><given-names>LM</given-names></name>,
            <etal/>.
            <article-title>MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer</article-title>.
            <source>Mol Cancer</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>18</volume>:
            <fpage>42</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-061">
          <label>61. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Zhang</surname><given-names>Q</given-names></name>,
            <name><surname>Tsui</surname><given-names>YM</given-names></name>,
            <name><surname>Zhang</surname><given-names>VX</given-names></name>,
            <name><surname>Lu</surname><given-names>AJ</given-names></name>,
            <name><surname>Lee</surname><given-names>JM</given-names></name>,
            <name><surname>Lee</surname><given-names>E</given-names></name>,
            <etal/>.
            <article-title>Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma</article-title>.
            <source>Theranostics</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>14</volume>:
            <fpage>892</fpage>-<lpage>910</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-062">
          <label>62. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Keshavarz</surname><given-names>M</given-names></name>,
            <name><surname>Ebrahimzadeh</surname><given-names>MS</given-names></name>,
            <name><surname>Miri</surname><given-names>SM</given-names></name>,
            <name><surname>Dianat-Moghadam</surname><given-names>H</given-names></name>,
            <name><surname>Ghorbanhosseini</surname><given-names>SS</given-names></name>,
            <name><surname>Mohebbi</surname><given-names>SR</given-names></name>,
            <etal/>.
            <article-title>Oncolytic Newcastle disease virus delivered by mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment</article-title>.
            <source>Virol J</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>17</volume>:
            <fpage>64</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-063">
          <label>63. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Gebhardt</surname><given-names>T</given-names></name>,
            <name><surname>Park</surname><given-names>SL</given-names></name>,
            <name><surname>Parish</surname><given-names>IA</given-names></name>.
            <article-title>Stem-like exhausted and memory CD8<sup>+</sup> T cells in cancer</article-title>.
            <source>Nat Rev Cancer</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>23</volume>:
            <fpage>780</fpage>-<lpage>798</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-064">
          <label>64. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Ascic</surname><given-names>E</given-names></name>,
            <name><surname>Pereira</surname><given-names>CF</given-names></name>.
            <article-title>Transcription factor-mediated reprogramming to antigen-presenting cells</article-title>.
            <source>Curr Opin Genet Dev</source>.
            <year iso-8601-date="2025">2025</year>;
            <volume>90</volume>:
            <fpage>102300</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-065">
          <label>65. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Zhang</surname><given-names>R</given-names></name>,
            <name><surname>Liu</surname><given-names>TY</given-names></name>,
            <name><surname>Senju</surname><given-names>S</given-names></name>,
            <name><surname>Haruta</surname><given-names>M</given-names></name>,
            <name><surname>Hirosawa</surname><given-names>N</given-names></name>,
            <name><surname>Suzuki</surname><given-names>M</given-names></name>,
            <etal/>.
            <article-title>Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells</article-title>.
            <source>Cancer Immunol Res</source>.
            <year iso-8601-date="2015">2015</year>;
            <volume>3</volume>:
            <fpage>668</fpage>-<lpage>677</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-066">
          <label>66. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Shephard</surname><given-names>MT</given-names></name>,
            <name><surname>Merkhan</surname><given-names>MM</given-names></name>,
            <name><surname>Forsyth</surname><given-names>NR</given-names></name>.
            <article-title>Human mesenchymal stem cell secretome driven T cell immunomodulation is IL-10 dependent</article-title>.
            <source>Int J Mol Sci</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>23</volume>:
            <fpage>13596</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-067">
          <label>67. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wang</surname><given-names>D</given-names></name>,
            <name><surname>Huang</surname><given-names>S</given-names></name>,
            <name><surname>Yuan</surname><given-names>X</given-names></name>,
            <name><surname>Liang</surname><given-names>J</given-names></name>,
            <name><surname>Xu</surname><given-names>R</given-names></name>,
            <name><surname>Yao</surname><given-names>G</given-names></name>,
            <etal/>.
            <article-title>The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus</article-title>.
            <source>Cell Mol Immunol</source>.
            <year iso-8601-date="2017">2017</year>;
            <volume>14</volume>:
            <fpage>423</fpage>-<lpage>431</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-068">
          <label>68. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Nozari</surname><given-names>P</given-names></name>,
            <name><surname>Mokhtari</surname><given-names>P</given-names></name>,
            <name><surname>Nemati</surname><given-names>M</given-names></name>,
            <name><surname>Zainodini</surname><given-names>N</given-names></name>,
            <name><surname>Taghipour</surname><given-names>Z</given-names></name>,
            <name><surname>Asadi</surname><given-names>F</given-names></name>,
            <etal/>.
            <article-title>Investigation of the effect of IFN-&#x03B3;/TNF-&#x03B1;-treated mesenchymal stem cells on Th9-and Treg cell-related parameters in a mouse model of ovalbumin-induced allergic asthma</article-title>.
            <source>Immunopharmacol Immunotoxicol</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>44</volume>:
            <fpage>773</fpage>-<lpage>785</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-069">
          <label>69. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Luo</surname><given-names>Y</given-names></name>,
            <name><surname>Guo</surname><given-names>J</given-names></name>,
            <name><surname>Zhang</surname><given-names>P</given-names></name>,
            <name><surname>Cheuk</surname><given-names>YC</given-names></name>,
            <name><surname>Jiang</surname><given-names>Y</given-names></name>,
            <name><surname>Wang</surname><given-names>J</given-names></name>,
            <etal/>.
            <article-title>Mesenchymal stem cell protects injured renal tubular epithelial cells by regulating mTOR-mediated Th17/Treg axis</article-title>.
            <source>Front Immunol</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>12</volume>:
            <fpage>684197</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-070">
          <label>70. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Court</surname><given-names>AC</given-names></name>,
            <name><surname>Le&#x2010;Gatt</surname><given-names>A</given-names></name>,
            <name><surname>Luz&#x2010;Crawford</surname><given-names>P</given-names></name>,
            <name><surname>Parra</surname><given-names>E</given-names></name>,
            <name><surname>Aliaga&#x2010;Tobar</surname><given-names>V</given-names></name>,
            <name><surname>B&#x00E1;tiz</surname><given-names>LF</given-names></name>,
            <etal/>.
            <article-title>Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response</article-title>.
            <source>EMBO Rep</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>21</volume>:
            <fpage>EMBR201948052</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-071">
          <label>71. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Ghorbani Alvanegh</surname><given-names>A</given-names></name>,
            <name><surname>Mirzaei Nodooshan</surname><given-names>M</given-names></name>,
            <name><surname>Dorostkar</surname><given-names>R</given-names></name>,
            <name><surname>Ranjbar</surname><given-names>R</given-names></name>,
            <name><surname>Jalali Kondori</surname><given-names>B</given-names></name>,
            <name><surname>Shahriary</surname><given-names>A</given-names></name>,
            <etal/>.
            <article-title>Antiproliferative effects of mesenchymal stem cells carrying <italic>Newcastle disease virus</italic> and <italic>Lactobacillus Casei</italic> extract on CT26 Cell line: Synergistic effects in cancer therapy</article-title>.
            <source>Infect Agents Cancer</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>18</volume>:
            <fpage>46</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-072">
          <label>72. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Zhao</surname><given-names>WH</given-names></name>,
            <name><surname>Cheng</surname><given-names>JX</given-names></name>,
            <name><surname>Shi</surname><given-names>PF</given-names></name>,
            <name><surname>Huang</surname><given-names>JY</given-names></name>.
            <article-title>Human umbilical cord mesenchymal stem cells with adenovirus-mediated interleukin 12 gene transduction inhibits the growth of ovarian carcinoma cells both <italic>in vitro</italic> and <italic>in vivo</italic></article-title>.
            <source>J South Med Univ</source>.
            <year iso-8601-date="2011">2011</year>;
            <volume>31</volume>:
            <fpage>903</fpage>-<lpage>907</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-073">
          <label>73. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Rui</surname><given-names>K</given-names></name>,
            <name><surname>Hong</surname><given-names>Y</given-names></name>,
            <name><surname>Zhu</surname><given-names>Q</given-names></name>,
            <name><surname>Shi</surname><given-names>X</given-names></name>,
            <name><surname>Xiao</surname><given-names>F</given-names></name>,
            <name><surname>Fu</surname><given-names>H</given-names></name>,
            <etal/>.
            <article-title>Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sj&#x00F6;gren&#x2019;s syndrome by modulating the function of myeloid-derived suppressor cells</article-title>.
            <source>Cell Mol Immunol</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>18</volume>:
            <fpage>440</fpage>-<lpage>451</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-074">
          <label>74. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Juin</surname><given-names>SK</given-names></name>,
            <name><surname>Ghosh</surname><given-names>S</given-names></name>,
            <name><surname>Majumdar</surname><given-names>S</given-names></name>.
            <article-title>Glycyrrhizic acid facilitates anti-tumor immunity by attenuating Tregs and MDSCs: An immunotherapeutic approach</article-title>.
            <source>Int Immunopharmacol</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>88</volume>:
            <fpage>106932</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-075">
          <label>75. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Rui</surname><given-names>X</given-names></name>,
            <name><surname>Alvarez Calderon</surname><given-names>F</given-names></name>,
            <name><surname>Wobma</surname><given-names>H</given-names></name>,
            <name><surname>Gerdemann</surname><given-names>U</given-names></name>,
            <name><surname>Albanese</surname><given-names>A</given-names></name>,
            <name><surname>Cagnin</surname><given-names>L</given-names></name>,
            <etal/>.
            <article-title>Human OX40L&#x2013;CAR-T<sub>regs</sub> target activated antigen-presenting cells and control T cell alloreactivity</article-title>.
            <source>Sci Transl Med</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>16</volume>:
            <fpage>eadj9331</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-076">
          <label>76. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Liu</surname><given-names>J</given-names></name>,
            <name><surname>Liu</surname><given-names>J</given-names></name>,
            <name><surname>Qin</surname><given-names>G</given-names></name>,
            <name><surname>Li</surname><given-names>J</given-names></name>,
            <name><surname>Fu</surname><given-names>Z</given-names></name>,
            <name><surname>Li</surname><given-names>J</given-names></name>,
            <etal/>.
            <article-title>MDSCs-derived GPR84 induces CD8<sup>+</sup> T-cell senescence via p53 activation to suppress the antitumor response</article-title>.
            <source>J Immunother Cancer</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>11</volume>:
            <fpage>e007802</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-077">
          <label>77. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Zhao</surname><given-names>Z</given-names></name>,
            <name><surname>Qin</surname><given-names>J</given-names></name>,
            <name><surname>Qian</surname><given-names>Y</given-names></name>,
            <name><surname>Huang</surname><given-names>C</given-names></name>,
            <name><surname>Liu</surname><given-names>X</given-names></name>,
            <name><surname>Wang</surname><given-names>N</given-names></name>,
            <etal/>.
            <article-title>FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion</article-title>.
            <source>J Hematol Oncol</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>17</volume>:
            <fpage>9</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-078">
          <label>78. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Pettinella</surname><given-names>F</given-names></name>,
            <name><surname>Mariotti</surname><given-names>B</given-names></name>,
            <name><surname>Lattanzi</surname><given-names>C</given-names></name>,
            <name><surname>Bruderek</surname><given-names>K</given-names></name>,
            <name><surname>Donini</surname><given-names>M</given-names></name>,
            <name><surname>Costa</surname><given-names>S</given-names></name>,
            <etal/>.
            <article-title>Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors</article-title>.
            <source>Cell Rep Med</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>5</volume>:
            <fpage>101380</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-079">
          <label>79. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Abo-Aziza</surname><given-names>FA</given-names></name>,
            <name><surname>Wasfy</surname><given-names>BM</given-names></name>,
            <name><surname>Wahba</surname><given-names>SM</given-names></name>,
            <name><surname>Abd-Elhalem</surname><given-names>SS</given-names></name>.
            <article-title>Mesenchymal stem cells and myeloid-derived suppressor cells interplay in adjuvant-induced arthritis rat model</article-title>.
            <source>Int Immunopharmacol</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>120</volume>:
            <fpage>110300</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-080">
          <label>80. </label>
          <mixed-citation publication-type="journal">
            <name><surname>He</surname><given-names>JY</given-names></name>,
            <name><surname>Huo</surname><given-names>FY</given-names></name>,
            <name><surname>Tang</surname><given-names>HC</given-names></name>,
            <name><surname>Liu</surname><given-names>B</given-names></name>,
            <name><surname>Bu</surname><given-names>LL</given-names></name>.
            <article-title>Myeloid-derived suppressor cells in head and neck squamous cell carcinoma</article-title>.
            <source>Int Rev Cell Mol Biol</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>375</volume>:
            <fpage>33</fpage>-<lpage>92</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-081">
          <label>81. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Keshavarz</surname><given-names>M</given-names></name>,
            <name><surname>Ebrahimzadeh</surname><given-names>MS</given-names></name>,
            <name><surname>Miri</surname><given-names>SM</given-names></name>,
            <name><surname>Dianat-Moghadam</surname><given-names>H</given-names></name>,
            <name><surname>Ghorbanhosseini</surname><given-names>SS</given-names></name>,
            <name><surname>Mohebbi</surname><given-names>SR</given-names></name>,
            <etal/>.
            <article-title>Correction to: Oncolytic Newcastle disease virus delivered by mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment</article-title>.
            <source>Virol J</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>17</volume>:
            <fpage>175</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-082">
          <label>82. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Joshi</surname><given-names>S</given-names></name>,
            <name><surname>Singh</surname><given-names>AR</given-names></name>,
            <name><surname>Liu</surname><given-names>KX</given-names></name>,
            <name><surname>Pham</surname><given-names>TV</given-names></name>,
            <name><surname>Zulcic</surname><given-names>M</given-names></name>,
            <name><surname>Skola</surname><given-names>D</given-names></name>,
            <etal/>.
            <article-title>SF2523: Dual PI3K/BRD4 inhibitor blocks tumor immunosuppression and promotes adaptive immune responses in cancer</article-title>.
            <source>Mol Cancer Ther</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>18</volume>:
            <fpage>1036</fpage>-<lpage>1044</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-083">
          <label>83. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Lan</surname><given-names>T</given-names></name>,
            <name><surname>Luo</surname><given-names>M</given-names></name>,
            <name><surname>Wei</surname><given-names>X</given-names></name>.
            <article-title>Mesenchymal stem/stromal cells in cancer therapy</article-title>.
            <source>J Hematol Oncol</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>14</volume>:
            <fpage>195</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-084">
          <label>84. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Tu</surname><given-names>Z</given-names></name>,
            <name><surname>Karnoub</surname><given-names>AE</given-names></name>.
            <article-title>Mesenchymal stem/stromal cells in breast cancer development and management</article-title>.
            <source>Semin Cancer Biol</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>86</volume>:
            <fpage>81</fpage>-<lpage>92</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-085">
          <label>85. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Weng</surname><given-names>Z</given-names></name>,
            <name><surname>Zhang</surname><given-names>B</given-names></name>,
            <name><surname>Wu</surname><given-names>C</given-names></name>,
            <name><surname>Yu</surname><given-names>F</given-names></name>,
            <name><surname>Han</surname><given-names>B</given-names></name>,
            <name><surname>Li</surname><given-names>B</given-names></name>,
            <etal/>.
            <article-title>Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer</article-title>.
            <source>J Hematol Oncol</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>14</volume>:
            <fpage>136</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-086">
          <label>86. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Fan</surname><given-names>M</given-names></name>,
            <name><surname>Zhang</surname><given-names>Y</given-names></name>,
            <name><surname>Shi</surname><given-names>H</given-names></name>,
            <name><surname>Xiang</surname><given-names>L</given-names></name>,
            <name><surname>Yao</surname><given-names>H</given-names></name>,
            <name><surname>Lin</surname><given-names>R</given-names></name>.
            <article-title>Bone mesenchymal stem cells promote gastric cancer progression through TGF-&#x03B2;1/Smad2 positive feedback loop</article-title>.
            <source>Life Sci</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>323</volume>:
            <fpage>121657</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-087">
          <label>87. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Zhang</surname><given-names>H</given-names></name>,
            <name><surname>Cao</surname><given-names>X</given-names></name>,
            <name><surname>Gui</surname><given-names>R</given-names></name>,
            <name><surname>Li</surname><given-names>Y</given-names></name>,
            <name><surname>Zhao</surname><given-names>X</given-names></name>,
            <name><surname>Mei</surname><given-names>J</given-names></name>,
            <etal/>.
            <article-title>Mesenchymal stem/stromal cells in solid tumor microenvironment: Orchestrating NK cell remodeling and therapeutic insights</article-title>.
            <source>Int Immunopharmacol</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>142</volume>:
            <fpage>113181</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-088">
          <label>88. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Moreno</surname><given-names>R</given-names></name>.
            <article-title>Mesenchymal stem cells and oncolytic viruses: Joining forces against cancer</article-title>.
            <source>J Immunother Cancer</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>9</volume>:
            <fpage>e001684</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-089">
          <label>89. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Gratwohl</surname><given-names>A</given-names></name>,
            <name><surname>Baldomero</surname><given-names>H</given-names></name>,
            <name><surname>Demirer</surname><given-names>TO</given-names></name>,
            <name><surname>Rosti</surname><given-names>G</given-names></name>,
            <name><surname>Dini</surname><given-names>G</given-names></name>,
            <name><surname>Ladenstein</surname><given-names>R</given-names></name>,
            <etal/>.
            <article-title>Hematopoetic stem cell transplantation for solid tumors in Europe</article-title>.
            <source>Ann Oncol</source>.
            <year iso-8601-date="2004">2004</year>;
            <volume>15</volume>:
            <fpage>653</fpage>-<lpage>660</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-090">
          <label>90. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Madjd</surname><given-names>Z</given-names></name>,
            <name><surname>Gheytanchi</surname><given-names>E</given-names></name>,
            <name><surname>Erfani</surname><given-names>E</given-names></name>,
            <name><surname>Asadi-Lari</surname><given-names>M</given-names></name>.
            <article-title>Application of stem cells in targeted therapy of breast cancer: A systematic review</article-title>.
            <source>Asian Pac J Cancer Prev</source>.
            <year iso-8601-date="2013">2013</year>;
            <volume>14</volume>:
            <fpage>2789</fpage>-<lpage>2800</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-091">
          <label>91. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Gunduz</surname><given-names>BO</given-names></name>,
            <name><surname>Atas</surname><given-names>E</given-names></name>.
            <article-title>Indirect hyperbilirubinemia because of eltrombopag in two cases after autologous hematopoetic stem cell transplantation</article-title>.
            <source>J Cancer Res Ther</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>19</volume>:
            <fpage>S970</fpage>-<lpage>S972</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-092">
          <label>92. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Barisic</surname><given-names>S</given-names></name>,
            <name><surname>Childs</surname><given-names>RW</given-names></name>.
            <article-title>Graft-versus-solid-tumor effect: From hematopoietic stem cell transplantation to adoptive cell therapies</article-title>.
            <source>Stem Cells</source>.
            <year iso-8601-date="2022">2022</year>;
            <volume>40</volume>:
            <fpage>556</fpage>-<lpage>563</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-093">
          <label>93. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Gandhi</surname><given-names>M</given-names></name>,
            <name><surname>Sharma</surname><given-names>B</given-names></name>,
            <name><surname>Nair</surname><given-names>S</given-names></name>,
            <name><surname>Vaidya</surname><given-names>AD</given-names></name>.
            <article-title>Current insights into CAR T-cell-based therapies for myelodysplastic syndrome</article-title>.
            <source>Pharm Res</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>41</volume>:
            <fpage>1757</fpage>-<lpage>1773</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-094">
          <label>94. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Aboul-Soud</surname><given-names>MA</given-names></name>,
            <name><surname>Alzahrani</surname><given-names>AJ</given-names></name>,
            <name><surname>Mahmoud</surname><given-names>A</given-names></name>.
            <article-title>Induced pluripotent stem cells (iPSCs)-roles in regenerative therapies, disease modelling and drug screening</article-title>.
            <source>Cells</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>10</volume>:
            <fpage>2319</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-095">
          <label>95. </label>
          <mixed-citation publication-type="journal">
            <name><surname>He</surname><given-names>R</given-names></name>,
            <name><surname>Weng</surname><given-names>Z</given-names></name>,
            <name><surname>Liu</surname><given-names>Y</given-names></name>,
            <name><surname>Li</surname><given-names>B</given-names></name>,
            <name><surname>Wang</surname><given-names>W</given-names></name>,
            <name><surname>Meng</surname><given-names>W</given-names></name>,
            <etal/>.
            <article-title>Application of induced pluripotent stem cells in malignant solid tumors</article-title>.
            <source>Stem Cell Rev Rep</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>19</volume>:
            <fpage>2557</fpage>-<lpage>2575</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-096">
          <label>96. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Zhang</surname><given-names>L</given-names></name>,
            <name><surname>Tian</surname><given-names>L</given-names></name>,
            <name><surname>Dai</surname><given-names>X</given-names></name>,
            <name><surname>Yu</surname><given-names>H</given-names></name>,
            <name><surname>Wang</surname><given-names>J</given-names></name>,
            <name><surname>Lei</surname><given-names>A</given-names></name>,
            <etal/>.
            <article-title>Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions</article-title>.
            <source>J Hematol Oncol</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>13</volume>:
            <fpage>153</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-097">
          <label>97. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Xue</surname><given-names>D</given-names></name>,
            <name><surname>Lu</surname><given-names>S</given-names></name>,
            <name><surname>Zhang</surname><given-names>H</given-names></name>,
            <name><surname>Zhang</surname><given-names>L</given-names></name>,
            <name><surname>Dai</surname><given-names>Z</given-names></name>,
            <name><surname>Kaufman</surname><given-names>DS</given-names></name>,
            <etal/>.
            <article-title>Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy</article-title>.
            <source>Trends Biotechnol</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>41</volume>:
            <fpage>907</fpage>-<lpage>922</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-098">
          <label>98. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Kumar</surname><given-names>D</given-names></name>,
            <name><surname>Gupta</surname><given-names>S</given-names></name>,
            <name><surname>Gupta</surname><given-names>V</given-names></name>,
            <name><surname>Tanwar</surname><given-names>R</given-names></name>,
            <name><surname>Chandel</surname><given-names>A</given-names></name>.
            <article-title>Engineering the future of regenerative medicines in gut health with stem cell-derived intestinal organoids</article-title>.
            <source>Stem Cell Rev Rep</source>.
            <year iso-8601-date="2025">2025</year>;
            <volume>21</volume>:
            <fpage>1449</fpage>-<lpage>1470</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-099">
          <label>99. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Bayik</surname><given-names>D</given-names></name>,
            <name><surname>Lathia</surname><given-names>JD</given-names></name>.
            <article-title>Cancer stem cell-immune cell crosstalk in tumour progression</article-title>.
            <source>Nat Rev Cancer</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>21</volume>:
            <fpage>526</fpage>-<lpage>536</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-100">
          <label>100. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Huang</surname><given-names>T</given-names></name>,
            <name><surname>Song</surname><given-names>X</given-names></name>,
            <name><surname>Xu</surname><given-names>D</given-names></name>,
            <name><surname>Tiek</surname><given-names>D</given-names></name>,
            <name><surname>Goenka</surname><given-names>A</given-names></name>,
            <name><surname>Wu</surname><given-names>B</given-names></name>,
            <etal/>.
            <article-title>Stem cell programs in cancer initiation, progression, and therapy resistance</article-title>.
            <source>Theranostics</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>10</volume>:
            <fpage>8721</fpage>-<lpage>8743</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-101">
          <label>101. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wang</surname><given-names>C</given-names></name>,
            <name><surname>Li</surname><given-names>Y</given-names></name>,
            <name><surname>Jia</surname><given-names>L</given-names></name>,
            <name><surname>Kim</surname><given-names>JK</given-names></name>,
            <name><surname>Li</surname><given-names>J</given-names></name>,
            <name><surname>Deng</surname><given-names>P</given-names></name>,
            <etal/>.
            <article-title>CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance</article-title>.
            <source>Cell Stem Cell</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>28</volume>:
            <fpage>1597</fpage>-<lpage>1613</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-102">
          <label>102. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Terzuoli</surname><given-names>E</given-names></name>,
            <name><surname>Bellan</surname><given-names>C</given-names></name>,
            <name><surname>Aversa</surname><given-names>S</given-names></name>,
            <name><surname>Ciccone</surname><given-names>V</given-names></name>,
            <name><surname>Morbidelli</surname><given-names>L</given-names></name>,
            <name><surname>Giachetti</surname><given-names>A</given-names></name>,
            <etal/>.
            <article-title>ALDH3A1 overexpression in melanoma and lung tumors drives cancer stem cell expansion, impairing immune surveillance through enhanced PD-L1 output</article-title>.
            <source>Cancers</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>11</volume>:
            <fpage>1963</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-103">
          <label>103. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Mortezaee</surname><given-names>K</given-names></name>.
            <article-title>Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer</article-title>.
            <source>J Biochem Mol Toxicol</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>35</volume>:
            <fpage>e22708</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-104">
          <label>104. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Rodr&#x00ED;guez</surname><given-names>MM</given-names></name>,
            <name><surname>Fiore</surname><given-names>E</given-names></name>,
            <name><surname>Bayo</surname><given-names>J</given-names></name>,
            <name><surname>Atorrasagasti</surname><given-names>C</given-names></name>,
            <name><surname>Garc&#x00ED;a</surname><given-names>M</given-names></name>,
            <name><surname>Onorato</surname><given-names>A</given-names></name>,
            <etal/>.
            <article-title>4Mu decreases CD47 expression on hepatic cancer stem cells and primes a potent antitumor T cell response induced by interleukin-12</article-title>.
            <source>Mol Ther</source>.
            <year iso-8601-date="2018">2018</year>;
            <volume>26</volume>:
            <fpage>2738</fpage>-<lpage>2750</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-105">
          <label>105. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Ho</surname><given-names>T</given-names></name>,
            <name><surname>Msallam</surname><given-names>R</given-names></name>.
            <article-title>Tissues and tumor microenvironment (TME) in 3D: Models to shed light on immunosuppression in cancer</article-title>.
            <source>Cells</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>10</volume>:
            <fpage>831</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-106">
          <label>106. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Ali</surname><given-names>S</given-names></name>,
            <name><surname>Borin</surname><given-names>TF</given-names></name>,
            <name><surname>Piranlioglu</surname><given-names>R</given-names></name>,
            <name><surname>Ara</surname><given-names>R</given-names></name>,
            <name><surname>Lebedyeva</surname><given-names>I</given-names></name>,
            <name><surname>Angara</surname><given-names>K</given-names></name>,
            <etal/>.
            <article-title>Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study</article-title>.
            <source>PLoS One</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>16</volume>:
            <fpage>e0246646</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-107">
          <label>107. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Yang</surname><given-names>M</given-names></name>,
            <name><surname>Li</surname><given-names>J</given-names></name>,
            <name><surname>Gu</surname><given-names>P</given-names></name>,
            <name><surname>Fan</surname><given-names>X</given-names></name>.
            <article-title>The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment</article-title>.
            <source>Bioact Mater</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>6</volume>:
            <fpage>1973</fpage>-<lpage>1987</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-108">
          <label>108. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Hawkins</surname><given-names>ER</given-names></name>,
            <name><surname>D&#x2019;Souza</surname><given-names>RR</given-names></name>,
            <name><surname>Klampatsa</surname><given-names>A</given-names></name>.
            <article-title>Armored CAR T-cells: The next chapter in T-cell cancer immunotherapy</article-title>.
            <source>Biologics</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>15</volume>:
            <fpage>95</fpage>-<lpage>105</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-109">
          <label>109. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Mashima</surname><given-names>H</given-names></name>,
            <name><surname>Zhang</surname><given-names>R</given-names></name>,
            <name><surname>Kobayashi</surname><given-names>T</given-names></name>,
            <name><surname>Tsukamoto</surname><given-names>H</given-names></name>,
            <name><surname>Liu</surname><given-names>T</given-names></name>,
            <name><surname>Iwama</surname><given-names>T</given-names></name>,
            <etal/>.
            <article-title>Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy</article-title>.
            <source>Mol Ther Methods Clin Dev</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>21</volume>:
            <fpage>171</fpage>-<lpage>179</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-110">
          <label>110. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Wang</surname><given-names>LT</given-names></name>,
            <name><surname>Liu</surname><given-names>KJ</given-names></name>,
            <name><surname>Sytwu</surname><given-names>HK</given-names></name>,
            <name><surname>Yen</surname><given-names>ML</given-names></name>,
            <name><surname>Yen</surname><given-names>BL</given-names></name>.
            <article-title>Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells</article-title>.
            <source>Stem Cells Transl Med</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>10</volume>:
            <fpage>1288</fpage>-<lpage>1303</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-111">
          <label>111. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Raturi</surname><given-names>M</given-names></name>,
            <name><surname>Das</surname><given-names>K</given-names></name>.
            <article-title>Ethical issues facing hematopoietic stem cell transplantation in India</article-title>.
            <source>Bull Cancer</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>108</volume>:
            <fpage>893</fpage>-<lpage>894</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-112">
          <label>112. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Novoa</surname><given-names>JJ</given-names></name>,
            <name><surname>Westra</surname><given-names>IM</given-names></name>,
            <name><surname>Steeneveld</surname><given-names>E</given-names></name>,
            <name><surname>Neves</surname><given-names>NF</given-names></name>,
            <name><surname>Arendzen</surname><given-names>CH</given-names></name>,
            <name><surname>Rajaei</surname><given-names>B</given-names></name>,
            <etal/>.
            <article-title>Good manufacturing practice-compliant human induced pluripotent stem cells: From bench to putative clinical products</article-title>.
            <source>Cytotherapy</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>26</volume>:
            <fpage>556</fpage>-<lpage>566</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-113">
          <label>113. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Lappin</surname><given-names>T</given-names></name>,
            <name><surname>Cheng</surname><given-names>T</given-names></name>.
            <article-title>An urgent need for standardization of stem cells and stem cell-derived products toward clinical applications</article-title>.
            <source>Stem Cells Transl Med</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>10</volume>:
            <fpage>S1</fpage>-<lpage>S3</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-114">
          <label>114. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Chouaib</surname><given-names>B</given-names></name>,
            <name><surname>Haack-S&#x00F8;rensen</surname><given-names>M</given-names></name>,
            <name><surname>Chaubron</surname><given-names>F</given-names></name>,
            <name><surname>Cuisinier</surname><given-names>F</given-names></name>,
            <name><surname>Collart-Dutilleul</surname><given-names>PY</given-names></name>.
            <article-title>Towards the standardization of mesenchymal stem cell secretome-derived product manufacturing for tissue regeneration</article-title>.
            <source>Int J Mol Sci</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>24</volume>:
            <fpage>12594</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-115">
          <label>115. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Li</surname><given-names>YR</given-names></name>,
            <name><surname>Dunn</surname><given-names>ZS</given-names></name>,
            <name><surname>Yu</surname><given-names>Y</given-names></name>,
            <name><surname>Li</surname><given-names>M</given-names></name>,
            <name><surname>Wang</surname><given-names>P</given-names></name>,
            <name><surname>Yang</surname><given-names>L</given-names></name>.
            <article-title>Advancing cell-based cancer immunotherapy through stem cell engineering</article-title>.
            <source>Cell Stem Cell</source>.
            <year iso-8601-date="2023">2023</year>;
            <volume>30</volume>:
            <fpage>592</fpage>-<lpage>610</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-116">
          <label>116. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Cheng</surname><given-names>C</given-names></name>,
            <name><surname>Tang</surname><given-names>N</given-names></name>,
            <name><surname>Li</surname><given-names>J</given-names></name>,
            <name><surname>Cao</surname><given-names>S</given-names></name>,
            <name><surname>Zhang</surname><given-names>T</given-names></name>,
            <name><surname>Wei</surname><given-names>X</given-names></name>,
            <etal/>.
            <article-title>Bacteria-free minicircle DNA system to generate integration-free CAR-T cells</article-title>.
            <source>J Med Genet</source>.
            <year iso-8601-date="2019">2019</year>;
            <volume>56</volume>:
            <fpage>10</fpage>-<lpage>17</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-117">
          <label>117. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Alqarni</surname><given-names>A</given-names></name>,
            <name><surname>Jasim</surname><given-names>SA</given-names></name>,
            <name><surname>Altalbawy</surname><given-names>FM</given-names></name>,
            <name><surname>Kaur</surname><given-names>H</given-names></name>,
            <name><surname>Kaur</surname><given-names>I</given-names></name>,
            <name><surname>Rodriguez&#x2010;Benites</surname><given-names>C</given-names></name>,
            <etal/>.
            <article-title>Challenges and opportunities for cancer stem cell&#x2010;targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell&#x2010;dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes</article-title>.
            <source>J Biochem Mol Toxicol</source>.
            <year iso-8601-date="2024">2024</year>;
            <volume>38</volume>:
            <fpage>e23719</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-118">
          <label>118. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Zhen</surname><given-names>A</given-names></name>,
            <name><surname>Carrillo</surname><given-names>MA</given-names></name>,
            <name><surname>Mu</surname><given-names>W</given-names></name>,
            <name><surname>Rezek</surname><given-names>V</given-names></name>,
            <name><surname>Martin</surname><given-names>H</given-names></name>,
            <name><surname>Hamid</surname><given-names>P</given-names></name>,
            <etal/>.
            <article-title>Robust CAR-T memory formation and function via hematopoietic stem cell delivery</article-title>.
            <source>PLoS Pathog</source>.
            <year iso-8601-date="2021">2021</year>;
            <volume>17</volume>:
            <fpage>e1009404</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-119">
          <label>119. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Kumar</surname><given-names>D</given-names></name>,
            <name><surname>Tanwar</surname><given-names>R</given-names></name>.
            <article-title>Advancing NK cell therapies: Expansion and activation for next-generation immunotherapy</article-title>.
            <source>Curr Cancer Ther Rev</source>.
            <year iso-8601-date="2026">2026</year>;
            <volume>22</volume>:
            <fpage>470</fpage>-<lpage>484</lpage>.
          </mixed-citation>
        </ref>
        <ref id="B-120">
          <label>120. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Mim</surname><given-names>TJ</given-names></name>,
            <name><surname>Ahmad</surname><given-names>I</given-names></name>,
            <name><surname>Basher</surname><given-names>SR</given-names></name>,
            <name><surname>Rahman</surname><given-names>MF</given-names></name>,
            <name><surname>Ambati</surname><given-names>SR</given-names></name>,
            <name><surname>Venkatagiri</surname><given-names>K</given-names></name>,
            <etal/>.
            <article-title>Stem cells in organogenesis and regeneration</article-title>.
            <source>Stem Cell Res Ther</source>.
            <year iso-8601-date="2026">2026</year>;
            <volume>17</volume>:
            <fpage>85</fpage>.
          </mixed-citation>
        </ref>
        <ref id="B-121">
          <label>121. </label>
          <mixed-citation publication-type="journal">
            <name><surname>Bryukhovetskiy</surname><given-names>I</given-names></name>,
            <name><surname>Pak</surname><given-names>O</given-names></name>,
            <name><surname>Khotimchenko</surname><given-names>Y</given-names></name>,
            <name><surname>Bryukhovetskiy</surname><given-names>A</given-names></name>,
            <name><surname>Sharma</surname><given-names>A</given-names></name>,
            <name><surname>Sharma</surname><given-names>HS</given-names></name>.
            <article-title>Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells microenvironment in glioblastoma</article-title>.
            <source>Int Rev Neurobiol</source>.
            <year iso-8601-date="2020">2020</year>;
            <volume>151</volume>:
            <fpage>67</fpage>-<lpage>98</lpage>.
          </mixed-citation>
        </ref>
      </ref-list>
  </back>
</article>